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ABSTRACT 
 
RAMIRO E. DIZ: Intrinsic mechanisms of regulation of anti-Sm B cell Anergy 
(Under the direction of Stephen H. Clarke, Ph.D) 
 
 
 
One of the fundamental properties of the immune system is its capacity to avoid 
autoimmune diseases. The mechanisms regulating this process, known as self-tolerance, are 
many and varied. Self-reactive B cells that are not deleted in the bone marrow are regulated 
by anergy in the periphery. This mechanism renders self-reactive B cells unresponsive to 
activating signals. The use of immunoglobulin transgenic mouse models specific for self or 
neo-self antigens have indicated that anergy encompasses a broad spectrum of complex and 
multi-factorial states of cell unresponsiveness. The work presented here addresses the 
regulatory complexity of anergy in anti-Sm B cells.  
 In this study using a high affinity anti-Sm mouse model, I have identified several 
mechanisms for anti-Sm B cell anergy.  In addition, I have shown that the mechanisms of 
anergy differ depending on affinity of the B cell receptor (BCR) for Sm and subset identity.  
High affinity anti-Sm B cells, unlike low affinity anti-Sm B cells, are unable to survive in the 
presence of competitor B cells. This defect correlates with a BAFF non-responsiveness and 
increased cell death.  Both high and low affinity anti-Sm follicular B cells express signaling 
competent BCRs, although BCR ligation induces rapid cell death, which correlates with an 
imbalance of pro and anti-apoptotic protein expression. In contrast, the BCRs expressed by 
 iii
marginal zone B cells from the high affinity mouse model are defective in signaling 
suggesting an uncoupling of the signalsome from the BCR on these cells.   
 Activation by toll-like receptors (TLRs) is also defective in anergic B cells.  I find 
that TLR-induced activation of anergic anti-Sm B cells is regulated by two mechanisms; 
activation induced cell death and a block in Plasma cell (PC) differentiation. The block in PC 
differentiation occurs prior to the expression of PC-specific genes. The importance of each 
mechanism to the regulation of B cells of different subset varies, with the block in PC 
differentiation not occurring efficiently until after B cells reach maturity.   
 Together, the data presented provide evidence of the complexity and variety of anti-
Sm B cells regulation and provide insight to the mechanisms of B cell anergy.  
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CHAPTER 1 
 
INTRODUCTION 
 
The immune system is a complex myriad of cells, organs and tissues working as a 
dynamic network with the purpose of protecting the body from infection. Understanding the 
mechanisms through which the immune system distinguishes self from foreign antigens is 
one of the most confounding and fundamental problems of immunology. This phenomenon, 
known as self-tolerance, is paramount for an efficient defense against pathogens and 
prevention of autoimmune diseases. Over the past 20 years, the introduction of genetically 
modified transgenic mice carrying rearranged B cell receptors has provided insight into the 
normal physiology and mechanisms of tolerance regulating B cells. Immunoglobulin (Ig) Tg 
mice have been used to determine mechanisms of tolerance such as central and peripheral 
deletion, anergy and follicular exclusion, among others. Nonetheless, more and more 
evidence shows that these mechanisms represent only a fraction of those that are involved in 
B cell regulation, and that these and other mechanisms vary greatly depending on the 
characteristics of the antigen and the affinity of the BCR. Therefore, it is of great importance 
to understand which mechanisms are invoked to induce tolerance and prevent autoimmunity. 
The work presented in this thesis is an initial characterization of a new Tg mouse model with 
a high BCR affinity for Smith (Sm) antigen, in which several novel mechanisms of tolerance 
have been determined. 
A. B cell development and maturation 
 B cell development is initiated in the bone marrow. Following several distinct stages 
of differentiation in which cells are subjected to various means of regulation or checkpoints, 
a pool of B cells expressing a diverse BCR repertoire is generated. These cells then migrate 
to the spleen where, after passing through more checkpoints, they undergo final maturation. 
 
1. Early B cell development 
 The development of B cells begins in the bone marrow, where haematopoietic stem 
cells give rise to a B and T cell precursor, or common lymphoid progenitor 1. The earliest B 
cell committed precursor is differentiated by the surface expression of B220; the B cell 
specific splice variant of CD45 2. Several stages of differentiation from this early B cell 
progenitor to the immature B cell expressing surface IgM have been described in detail  1, 3. 
Early stages of B cell development have a high dependency on cytokines, such as FLT3 
ligand and IL-7, for survival and proliferation 4. As B cells progress through the different 
stages, they become less dependent on cytokines and more dependent on signaling, induced 
via the pre-BCR and BCR complex, for their survival 3, 5, 6, 7. 
  During early B cell development, multiple VH, DH and JH Ig gene segments are 
randomly rearranged and assembled in a stepwise manner to generate the final IgM 8. With 
the help of recombinases RAG1 and RAG2 and other enzymes, DH to JH rearrangement is 
initiated at the pro-B cell stage, followed by VH to DHJH rearrangement which generates the 
IgH or µH chain. The newly formed µH chain associates with a surrogate light chain formed 
by VpreB and λ5 proteins, and together they are shuttled to the cell surface in association 
with the signaling proteins Igα and Igβ as the pre-BCR at the large pre-B cell stage 9, 10, 11, 12. 
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Cells with a productive pre-BCR undergo rapid clonal expansion 13, 14. This is a critical check 
point in early development where up to 75 percent of large pre-B cells are eliminated due to 
failure of the Ig chain to associate with the surrogate L chain. Lack of µH chain, Igα or λ5 
blocks B cell development at this stage, demonstrating the importance of the pre-BCR and 
signals induced by it for further B cell development  3, 5, 6, 15, 16.    
 In the next stage, (small pre-B) B cells re-express RAG genes and undergo IgL chain 
rearrangement, VL to JL 15, 17. After productive rearrangement, the new IgL chain associates 
with the IgH chain and is expressed on the surface of immature B cells. At this stage, B cells 
undergo another major checkpoint. Cells lacking  a functional light chain rearrangement, 
arrest and undergo cell death, as demonstrated by mice deficient in both κ and λ light chains 
18, 19, 20. At this stage, central tolerance mechanisms test the reactivity of the BCR for self-
antigens, and cells that respond positively are eliminated by negative selection 5, 15, 21. Other 
mechanisms of regulation occur at this stage, and these will be discussed below. The 
immature B cells which are not eliminated migrate to the periphery, more specifically to the 
spleen, and undergo further maturation.   
 
2. Peripheral B cell maturation 
2.1 Transitional B cells.  
Newly formed immature B cells emigrate from the bone marrow to the spleen where 
they undergo further selection and maturation to long lived follicular (Fo), marginal zone 
(MZ) or B1 B cells. These cells are termed transitional (Tr) B cells and are distinguished by 
surface markers such as IgMhi, IgDlo, CD23-, CD21- and AA4.1+ ( ). Tr B cells have a short 
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half-life and most will be eliminated by negative selection – only 20-50% will enter the pool 
of mature B cells 22  23. 
 Several transitional stages prior to full B cell maturation have been described. 
Originally, Carsetti described these transitional cells and subdivided them into two groups: 
T1 and T2; the latter expressing high levels of CD21 and CD23 on their cell surface 24, 25. 
Later studies have questioned the validity of these subpopulations on the ability to properly 
distinguish T2 from MZ B cells  25, 26.  
More recent work by Allman, determined that transitional cells expressed CD93 
(C1qRp), which is recognized by both 493 and AA4.1 monoclonal antibodies 23, 27. Using this 
new marker together with CD21, CD23 and IgM, three distinct Tr subpopulations where 
determined (T1, T2 and T3) which are easily separated from MZ and Fo B cells. All three Tr 
B cell subpopulations are unable to proliferate in response to anti-IgM and undergo rapid cell 
death 23, 28. Here I will refer to Tr B cells as one population defined as CD23- and CD21-. 
 
2.2 Mature B cells.  
Long live mature B cells that derive from Tr cells are further divided into Fo, MZ and 
B1 subsets 1. The cells of these subsets are distinguished based on surface markers, 
anatomical localization and function 29. Fo B cells have a half-life of 6 to 10 weeks, make up 
to 70 to 80 percent of all B cells present in the spleen and are also found in lymph nodes 23, 25, 
30, 31. Anatomically, they are found in the lymphoid follicles of the spleen and lymph nodes. 
They are generally described as IgMlo, IgDhi B220hi, CD21int, CD23hi, CD93-, CD9- and 
CD1dlo  32, 33. Fo B cells are able to respond to T-cell dependent and T-cell independent 
antigen-driven activation and are involved in primary and secondary responses. Even so, they 
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are responsible for most of the IgG antibodies produced following an immune response  34. 
These cells also undergo somatic hypermutation and affinity maturation in germinal center 
reactions 35, 36, 37. 
 MZ B cells make up 5 to 10 percent of B cells in the spleen. They are also long live 
and self-replenishing. Evidence indicates that recruitment and selection of MZ-B cells occurs 
on the basis of positive selection via the BCR and likely driven by self antigen  38, 39. These 
cells are found in the external boundary of the follicle and the marginal sinus. Blood enters 
the spleen, exits circulation through the marginal sinus and flows through the marginal zone 
40. Therefore MZ B cells are in a privileged position to detect blood-born pathogens or 
particulate antigens. It is not surprising then that MZ B cells are the primary line of defense 
against these pathogens. Upon encountering antigen, MZ B cells are rapidly activated and 
induce secretion of IgM  29, 34, 38, 41, 42, 43. MZ B cells express higher levels of complement 
receptors, MHC molecules and toll-like receptors than Fo B cells, which might explain their 
ability to respond quickly and allowing them to link the innate and adaptive immune systems 
44. They are also important in Ag presentation to T cells and can act as potent T cell 
activators 45. Although MZ B cells are traditionally considered to be important only in T-
independent activation, it has been demonstrated in recent years that these cells are also 
important in T-dependent activation, and that they can undergo class switching and somatic 
hypermutation  42, 46, 47. 
 B-1 B cells usually are divided into B1a and B1b subpopulations based on the 
expression of CD5 on the surface of B1a cells. Together with MZ B cells, B1 B cells are 
responsible for the production of ‘natural’ antibodies and are recruited and activated early in 
the response, as another component of the first line of defense to T-independent type 2 
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antigens. They can be found in small numbers in the spleen of wild type mice, but are mainly 
found in the peritoneal cavity 48. They are long lived cells and are able to replenish 
themselves. Most of these cells have BCRs that grant them autoreactivity, and a preferential 
usage of VH and VL genes which, taken together, suggest these cells have been positively 
selected. B1 B cells are produced early in prenatal development from fetal liver stem cells 
but can also be produced in adult bone marrow 49, 50, 51.  
 
2.3. Fo vs MZ vs B1 B cell fate.  
B cell development and maturation is regulated by many intrinsic and extrinsic 
factors. Although I will not describe every factor here, I will attempt to summarize those 
most important to the process. 
 The lack of pre-BCR has already been mentioned as a factor for B cell development 
in the BM. A lack of the pre-BCR, and therefore a lack of signaling induced by it, block 
further development of the B cells at the pro-B cell stage  16. B cells that emigrate to the 
spleen express a mature rearranged BCR. Work from the Rajewsky laboratory has 
demonstrated that the lack of a mature BCR, or its subsequent ability to signal (Igα 
inactivation), was sufficient to induce a loss of peripheral mature Fo B cells; MZ B cells 
were only slightly affected 52, 53. These data support the hypothesis that B cells require a 
“tonic” BCR induced signal for survival. To date, the nature of and the ligand involved in 
this “tonic” signal remains unresolved. 
 BCR signaling is not only important in the maintenance of the peripheral mature B 
cell pool, but also influences the fate of B cells, as it is responsible for dictating into which 
mature pool the cells will enter  43. Multiple lines of evidence from different groups using 
6
transgenic and knock-out mice support a hypothesis that BCR signal strength determines or 
influences whether a B cell will enter the Fo, MZ or B1 pool of cells.  
 Several pieces of evidence using Tg mice over-expressing positive regulators of BCR 
signaling (CD19), or eliminating them (CD19, p85 and p110 subunits of PI3K), or lacking 
negative regulators of BCR signaling (SHP-1, CD22, CD72) suggest that strong BCR signals 
result in the production of B1 and MZ cells, while low BCR signals generate Fo B cells 38, 54, 
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66. More evidence to this effect was recently provided through the 
use of a mouse expressing LMP2A in varied amounts. LMP2A (a component of the Epstain-
Barr Virus) mimics the BCR and induces signaling. B cells that expressed higher levels of 
LMP2A became B1 cells while cells with lower levels became Fo and MZ B cells 67, 68. 
Nonetheless, others have argued that low BCR signaling favors MZ B cell production 
while stronger signals favors Fo B cell production 33. The complexity of BCR signaling 
makes these results difficult to reconcile into a simple model of maturation based solely on 
BCR signal strength. It is more likely that a combination of the quality and quantity of the 
signal, the form of the antigen as well as other extrinsic factors, contribute to produce the 
various cell types. For example, several transcription factors have been shown to be 
important in the final fate of maturation of B cells. Aiolos deficient mice have strong BCR 
signal strength but reduced MZ B cells 69. Similar defects are observed in mice defective in 
Notch-2 70, 71. In addition, extrinsic factors such as cytokines or secreted ligands of the TNF 
family (such as BAFF; described below) can also alter peripheral B cell maturation. 
Therefore, peripheral B cell development is a complex multifactor process in which normal B 
cell development might be shifted to favor one mature subset over another in the presence of 
a shortage or excess of certain components. 
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2.4 BAFF and peripheral B cell maturation.  
Several independent groups cloned a ligand, belonging to the TNF family, which 
promoted B cell survival and was subsequently named BAFF (B cell activating factor 
belonging to the TNF family)  72. Several other names have been used (TALL-1, THANK, 
BLyS, etc), but to avoid confusion BAFF will used here  73, 74. BAFF is produced and 
secreted by many cell types including monocytes, macrophages, DCs and neutrophils, but it 
was recently shown that the major source of BAFF is radiation-resistant stromal cells  41, 73, 75, 
76.  
 There are three BAFF receptors: B cell maturation antigen (BCMA), transmembrane 
activator and cAML interactor (TACI) and BAFF-R (also known as BR3). In addition to 
BAFF, there exists another ligand known as APRIL (a proliferation-inducing ligand) that 
binds only to BCMA and TACI. The expression pattern of all three BAFF receptors is highly 
regulated in B cell development 77. BCMA is expressed mainly in plasma cells (PC) and pre-
PCs and plays a role in PC survival 78, 79, 80. TACI is expressed in both Fo and MZ B cells. 
TACI deficient mice have an increased number of peripheral B cells, which lead to the 
conclusion that TACI acts as a negative regulator of BAFF signaling 81. Nonetheless, TACI 
might play a positive role in B cell activation as demonstrated by a defective response to T-
independent type 2 antigens  82. The major evidence of the role BAFF plays as a survival 
factor for B cells was demonstrated by BAFF or BAFF-R deficient mice in which B cell 
maturation is impaired following T1 stage of B cell development  83, 84. Furthermore, excess 
BAFF promotes enhanced Fo and MZ B cell numbers  85.  
 The signaling pathways induced by BAFF that lead to B cell survival have been 
complicated by the fact that most cells express multiple BAFF receptors. Several pathways 
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known to be activated by BAFF include: Akt, ERK, Pim2, NF-κB1 and 2, etc 86, 87, 88, 89. 
Woodland et al. have recently proposed a model in which Akt signaling inhibits Bim 
upregulation (a pro-apoptotic protein) by inhibiting Foxo3a and by increasing the expression 
of Mcl-1 which blocks Bim expression as well 77. In addition, ERK activation by BAFF has 
been proposed to inhibit Bim 90. The NF-κB pathways activated by BAFF induce 
upregulation of Bcl-xL, A1 and Bcl2, which act as pro-survival molecules inhibiting 
apoptosis 91. In section B.3 we will further discuss the role of BAFF in B cell activation. 
  
B.  B cell activation 
 B cell activation results in antibody production and secretion that is necessary for an 
efficient immune response against foreign pathogens. B cells sense the environment via their 
BCRs, as well as through other receptors such as toll-like receptors. Ligation of these 
receptors induces a complex signaling pattern that activates transcription factors, induces 
gene expression changes and ultimately results in B cell proliferation, antibody secretion or 
cell death. The context in which the B cells are activated, as well as the balance between the 
signaling pathways, dictate the final outcome of activation.  In this section, I will review the 
signaling pathways induced by BCR, TLRs and BAFF ligation, and their effects on the 
biology of B cells.  
 
1. BCR induced activation 
1.1. BCR induced signaling pathways 
The B cell receptor is composed of a membrane Ig associated non-covalently with the 
Igα/Igβ heterodimers containing an immunoreceptor tyrosine-based activation motif 
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(ITAM). Antigen-induced aggregation of the BCR complex results in phosphorylation of the 
ITAMs, and recruitment and activation of protein-tyrosine kinases (PTKs), which include 
Lyn, Btk and Syk, and leads to the formation of the BCR signalosome 92. BCR ligation also 
induces mobilization of Igα/Igβ into the ‘lipid rafts’ where there is a higher concentration of 
PTKs. BCR cross-linking leads to the phosphorylation of many interconnecting downstream 
signaling pathways, but four major pathways can be described 93. 
Syk induces phosphorylation of BLNK (SLP-65) which acts as an adaptor molecule 
and provides a platform for other effector molecules that in turn activate several diverging 
signaling pathways 94. BLNK phosphorylation is essential for activation of Bruton’s tyrosine 
kinase (Btk) and phospholipase C (PLC) γ2  95. PLCγ2 recruitment leads to the formation of 
inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of Ca2+, which, 
via the calmodulin-dependent serine phosphatase calcineurin, induces NFAT translocation to 
the nucleus. Transcription factor NFAT plays a mayor role in B cell survival and 
differentiation 96. DAG formation activates protein kinase C (PKC), which, in synergy with 
other pathways, activates the NF-κB signaling pathway 93.  
BCR-Ag engagement induces the recruitment and activation of the Ras/Raf/MEKK 
cascade via BLNK and Bam32  97, 98. This pathway leads to the activation of ERK. A 
downstream target of ERK activation is c-Myc (a proto-oncogene) which induces B cell 
proliferation 99. However, ERK activation plays other roles in cell survival and differentiation. 
Other members of the mitogen-activated protein kinase family – JNK and p38 – are also 
activated by BCR ligation, and lead to the phosphorylation of multiple transcription factors.   
PTK Lyn acts as both a positive and negative regulator of BCR induced signaling. 
Lyn exerts its positive role in activation via association with CD19, leading to the activation 
10
of Phosphoinositide-3 kinase (PI3K), among other pathways 100. A major downstream target 
of PI3K is Akt, or protein kinase B. Akt is involved in cellular survival pathways, where it 
directly and indirectly inhibits apoptotic processes 101.  
As I will address in section D, changes in the ability to signal following BCR ligation 
could prevent autoreactive B cells from being activated and therefore maintain tolerance. 
Nonetheless, changes in BCR signaling that lead to enhanced B cell survival might rescue 
autoreactive B cells that would normally be eliminated from the peripheral repertoire. 
 
1.2. Cell death regulation by BCR 
    B cell death or survival is largely decided by members of the Bcl-2 family of 
proteins. Pro-survival members include Bcl-2, Bcl-XL, MCL-1 and A1, while pro-apoptotic 
members include BAX, BAK and BH3-only proteins Bim, Bad and Bid. A balance between 
the expression and interaction of pro- and anti-apoptotic proteins dictates the fate of B cells. 
These proteins are regulated by both transcriptional and post-transcriptional mechanisms. 
The pro-apoptotic proteins described here usually mediate cell death via the mitochondrial 
pathway 102, 103, 104, 105. 
 The initiating factor of B cell death is thought to be the activation of BH3-only 
proteins. These proteins are thought to sequester anti-apoptotic proteins or directly activate 
BAX or BAK, although disagreements remain about the initiating events. The subsequent 
event is the oligomerization of BAK and BAX on the outer membrane of the mitochondria, 
which results in the permeabilization of the membrane, and the release of cytochrome c from 
the mitochondria to the cytoplasm. Released cytochrome c is then able to bind to apoptotic-
protease-acting factor 1 (Apaf1), which activates and oligomerizes caspase-9, forming the 
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apoptosome. Caspase-9 activation is paramount in the induction of B cell death and leads to 
caspase-3 activation as well. Pro-survival proteins like Bcl-2, Bcl-xL and MCL-1 are thought 
to oppose cell death by binding and sequestering BAX and BAK, thereby inhibiting their 
oligomerization  106, 107, 108, 109. Overexpression of Bcl-2 and Bcl-XL result in reduced BCR-
induced negative selection and an accumulation of B cells in Tg mice 110, 111, 112. B cells 
lacking BAX and BAK are refractory to apoptosis induction by BCR stimulation. Moreover, 
an accumulation of transitional and Fo B cells is observed in mice lacking both BAX and 
BAK, suggesting there could be a defect in negative B cell selection 113.  
Upon activation, BH3-only proteins interact with pro-survival proteins releasing BAX 
and BAK which are then able to oligomerize and induce cell death. Of the BH3-only 
proteins, Bim is a key player in the induction of B cell death, and its deletion results in 
enhanced B cell survival and autoimmunity. Bim can bind to all pro-survival proteins 
whereas other pro-apoptotic proteins are more specific and only bind a few members. As 
mentioned above, these proteins are regulated by multiple mechanisms. Bim expression is 
induced following BCR ligation, but BCR ligation also induces ERK signaling that results in 
Bim phosphorylation, which leads to its degradation. In addition, ubiquitination of Bim 
might also lead to its regulation 114, 115.  
 In addition to ERK, other signaling pathways such as Akt and NF-κB have been 
implicated in the regulation of apoptosis.  BAD, a BH3-only protein is a direct target of Akt. 
In its unphosphorylated state, BAD induces apoptosis, but, when phosphorylated by Akt, it 
binds to 14-3-3 protein inhibiting its binding to Bcl-2 116. Furthermore, Akt activation can 
inhibit apoptosis via BAD-independent mechanisms. These include increased expression of 
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MCL-1 and NF-κB activation. NF-κB signaling induces the expression of pro-survival 
proteins such as Bcl-2, Bcl-XL and A1 106. 
 It is important to note that not only are the signaling pathways important in dictating 
B cell survival or death, but also the quality of the signal. For example, transient ERK 
activation promotes BCR induced apoptosis, while sustained ERK signaling results in 
proliferation and survival. 
 
2. TLR induced activation 
 Toll-like receptors (TLRs) are members of the toll/interleukin-1 receptor superfamily. 
To date, more than 10 members of this superfamily have been described. TLRs recognize a 
variety of ligands, known as Pathogen-Associated Molecular Patterns (PAMPs), which 
include ligands from viruses, bacteria, fungi and parasites. TLRs are important in innate 
immunity, but also play a vital role in adaptive immunity and T-dependent B cell activation 
117, 118, 119. 
 B cells express a variety of TLRs, including TLR3, TLR4, TLR7 and TLR9 among 
others. In B cells, lipopolysacharide (LPS) is recognized by both the TLR4/MD2 and 
RP105/MD1 complex (a TLR-like receptor) 120. The downstream effects of TLR engagement 
by B cells are not yet fully understood. TLRs can induce, independently or as co-stimulants, 
B cell proliferation, class switching and differentiation to antibody secreting cells. This 
activation is independent of BCR specificity and therefore has the potential to activate 
autoreactive B cells. Much of the work on TLR induced activation of B cells has focused on 
TLR4, TLR9 and, to a lesser extent, TLR3 and TLR7 121.  
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 TLR engagement induces intracellular signaling pathways, leading to multiple 
downstream effectors and physiological events. The proximal events following TLR ligation 
vary depending on which TLR is engaged. TLR4 ligation induces association with several 
adaptor proteins. MyD88 is a central adaptor used by most TLRs. MyD88 associates with 
members of the interleukin-1 receptor associated kinases (IRAKs) family, which induces 
activation of MAPKs pathways as well as NF-κB pathway via TRAF6. A MyD88-
independent pathway exists for some TLRs, including TLR4. This pathway is initiated by 
Trif and TRAM adaptor proteins, which lead to other downstream events, and demonstrate 
overlapping roles with the MyD88 pathway as they are also involved in the activation of NF-
κB and MAPKs 122. Additionally, RP105 has been shown to signal in B cells via CD19’s 
activation of Lyn and Vav, which subsequently lead to PI3K activation 123. 
 As mentioned above, these pathways lead to polyclonal B cell proliferation, survival 
and differentiation to PCs. TLR engagement can also lead to rescue from apoptosis, 
activation and PC differentiation of transitional B cells, which are normally induced to 
undergo cell death following BCR engagement. This can have a profound impact on B cell 
tolerance as I will discuss later. 
 
3. BAFF role in B cell activation 
 The role of BAFF in B cell development has been extensively examined. It has been 
demonstrated that BAFF plays an important role in B cell activation following BCR or TLR 
engagement, and also in PC maintenance. BAFF exerts its influence on B cell activation in 
two ways; first by inducing and enhancing B cell survival, and secondly by enhancing B cell 
metabolism and cell cycling (although BAFF alone does not induce proliferation) 124, 125. 
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 Several lines of evidence indicate that BAFF enhances B cell survival following 
activation by upregulating Bcl-2, Bcl-XL and A1 via NF-κB (p50 and p52) signaling 89, 126. 
Nonetheless, others have obtained contradicting results generating a controversy on the true 
importance of these anti-apoptotic factors, and if they are indeed upregulated by BAFF. 
Recent work by Thompson’s group suggests that B cell survival induced by BAFF is as a 
result of Akt activation. Their work indicates that Akt induces the expression of MCL-1, a 
pro-survival protein, which binds and inhibits Bim. Furthermore, Akt phosphorylates and 
inhibits FOXO3, a transcription factor required for Bim expression. ERK activation by BAFF 
can also lead to Bim phosphorylation and degradation. Regardless of the induction or lack 
thereof of pro-survival proteins, BAFF appears to target and inhibit Bim, therefore enhancing 
B cell survival following activation 77. 
 BAFF stimulation does not induce cell cycling, but instead upregulates and sets the 
machinery involved in B cell proliferation. Furthermore, BAFF enhances cell metabolic 
activity and cell size. All these physiological changes appear to work concurrently to induce 
a more robust and quicker response following B cell activation 127. Therefore, BAFF acts not 
only as a survival factor, but also plays an important role in B cell activation. As would be 
predicted by these functions, BAFF has a major impact on B cell tolerance. 
 
C. Plasma cell differentiation 
 B cell activation induces proliferation, survival or cell death. Productive B cell 
activation by appropriate stimuli (BCR + T cell help, TLR stimulation, etc) can result in B 
cell differentiation to PCs. The end result of PC differentiation is the production and 
secretion of antibodies by B cells to induce an effective humoral immune response 128. 
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 PC differentiation is a complex and highly regulated process involving multiple 
transcription factors leading to terminal differentiation and antibody secretion. Several key 
transcription factors have been identified in PC differentiation, including B lymphocyte-
induced maturation protein 1 (BLIMP-1/prdm1), which has been described as the master 
regulator of PC differentiation. Enforced expression of Blimp-1 alone induces PC 
differentiation, while deletion of Blimp-1 inhibits B cells from becoming PCs. Blimp-1 
exerts its regulatory control primarily by repressing gene expression, although some genes 
have been shown to be induced by Blimp-1 128, 129.  
Nonetheless, Blimp-1 is not the only important protein in PC differentiation, and the 
process remains far from been completely understood. As an example, multiple PC 
intermediate stages (plasmablast) have been described, but it is yet not known how these 
stages are related to one another; if they are intermediates of a single pathway leading to PCs 
or if they result in different types of PCs. Furthermore, efforts are ongoing to determine 
which factors lead to the generation of short versus long-lived PCs 130, 131, 132, 133, 134. 
 Expression of Blimp-1 inhibits B cell proliferation by inhibiting c-Myc and inducing 
p18 (CDK inhibitor), consistent with the non-proliferative nature of PCs 127, 135. Blimp-1 also 
inhibits PAX5 (BSAP), a transcription factor key in maintaining B cell identity. Additionally, 
Blimp-1 inhibits BCL6, a repressor and key regulator of Blimp-1 itself. BCL6 is highly 
expressed in B cells found in germinal centers where affinity maturation and selection 
occurs. Once BCL6 is downregulated, Blimp-1 can induce PC differentiation. In addition to 
BCL6, data suggests that PAX5 can also regulate Blimp-1 expression. Decreases in PAX5 or 
BCL6 independently can lead to Blimp-1 upregulation. PAX5 is known to repress the 
expression of several proteins involved in antibody secretion, such as XBP-1, J chain and 
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IgH and IgΚ. XBP-1 is critical in controlling the response to endoplasmatic reticulum stress 
or unfolded protein response (UPR), which occurs during antibody production. Although 
PAX5 downregulation by Blimp-1 is sufficient for the induction of XBP-1, other factors may 
act in synergy to maximize XBP-1 expression 128, 129, 136.  
 IRF-4 (Interferon regulatory factor 4) is another transcription factor expressed in PCs. 
IRF-4 deficient mice lack detectable serum Ig, which indicates its importance in PC 
differentiation. IRF-4 is expressed in B cells expressing CD138 (pan PC marker) and Blimp-
1. Its role is not completely understood but it is known to activate both κ and λ light chain 
enhancers 137, 138.  
 The external factors leading to Blimp-1 expression are not yet fully understood. 
TLRs, IL-2 + IL-5, and IL-6 induce Blimp-1 expression but it is uncertain if this occurs as a 
direct consequence of or because of the downregulation of BCL-6. 
  
D. Mechanisms of B cell Tolerance 
 B cells produced in the bone marrow (BM) express a variety of BCR specificities due 
to the reshuffling and combination of different elements of the IgH and IgL chains 6. This 
wide repertoire of BCRs is critical to ensure an efficient immunological response to the 
multitude of bacterial and viral pathogens. Nonetheless, this process also produces B cells 
harboring BCRs with specificities for self or auto-antigens. Some reports suggest that as 
much as 50 to 70 percent of B cells produced in the BM are self-reactive 139, 140. If unchecked, 
B cells could induce disease following activation, as has been shown in multiple diseases 
which are characterized by the presence of auto-antibodies, specific to a self-antigen. 
Nevertheless, most individuals (and mice) show no signs of autoimmune disease because 
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there are mechanisms in place that delete, silence or control autoreactive B cells and inhibit 
their activation. This regulation is known as tolerance 141.  
 Thanks to the advent of genetically modified mice, in particular, transgenic mice 
bearing rearranged Ig genes specific for self or neo-self antigens, several of these 
mechanisms have been identified and our understanding of tolerance has greatly improved, 
even though much remains unknown 142, 143, 144, 145. One major observation is that there are 
multiple mechanisms involved in tolerance, and that they can act alone or in combination to 
maintain tolerance. Unknown is what triggers one mechanism over another in order to 
maintain tolerance. It has been proposed that the strength of the BCR signal and the form of 
the antigen play a key role in dictating which particular mechanism of tolerance is induced.  
 Studies using Ig-Tg models have established a hierarchy of mechanisms influencing 
the fate of auto-reactive B cells. 
 
Receptor Editing 
 Receptor editing is a process by which self-reactive, immature B cells in the BM 
upregulate RAG genes and undergo secondary rearrangement of the Ig in order to modify 
their BCR specificity 146, 147, 148, 149, 150, 151. Rearrangement occurs primarily to modify the light 
chain, although it can modify the heavy chain as well 149, 152, 153, 154. It is thought that 
rearrangement is the first mechanism to act upon autoreactive B cells, and that this occurs at 
a high frequency in non-transgenic B cells as well 146, 155, 156.  
 Several Ig-Tg models have been instrumental in demonstrating B cell receptor editing 
as a mechanism of tolerance. In the anti-dsDNA model (VH3H9 and VH3H9/56R), which 
expresses a heavy chain Ig from a hybridoma derived from MRL/lpr autoimmune mice, B 
18
cells that exit the BM have preferentially edited their light chain and there are relatively few 
IgL chains that can be used to form a non-DNA binding BCR 157, 158. This process is 
exemplified when VH3H9 mice were crossed to the Vκ4 light chain Tg mice, in which most 
B cells expressed the heavy chain, but not the light chain 147. Receptor editing can also be 
observed in the anti-H-2Kk,b mice where cells continue to express RAG genes and undergo, 
in some cases, light chain rearrangement 149. When these B cells are unable to receptor edit 
(RAG -/- or JH -/-), they are eliminated by apoptosis, a process known as central deletion 
(below) 159.  
 One interesting consequence of receptor editing has been the generation of dual BCR 
expressing B cells. In some cases the expression of a non-autoreactive BCR is thought to 
dilute the autoreactive BCR and therefore allow some “autoreactive” B cell to survive and 
mature. An example of this is seen in the VH3H9/56R where some B cells express both 
kappa and lambda light chains, particularly the MZ B cells 160. 
  
Central Deletion 
Central deletion is the way in which autoreactive B cells are physically eliminated 
from the immune repertoire before exiting the BM and migrating to the periphery. Central 
deletion is thought to occur if receptor editing has been incapable of eliminating BCR 
autoreactivity.  
The role of central deletion as a mechanism of tolerance was determined using Ig-Tg 
mice. Initial evidence came from the anti-H-2Kk,b model where B cells expressed a BCR 
specific for H-2K k or b. When the transgene was crossed to H-2Kk,b expressing mice, there 
was a marked reduction in peripheral B cell numbers compared to control mice expressing 
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H2Kd  144. Other systems where central deletion plays a significant role in maintaining 
tolerance have also been described. Double transgenic mice expressing anti-lysozyme Ig 
(anti-HEL) and membrane bound HEL resulted in the complete elimination of B cells in the 
BM 161. This contrasts the model in which HEL is secreted and anti-HEL cells are rendered 
anergic (see below).  
The VH3H9 Ig paired to several light chains results in BCRs capable of binding 
dsDNA. Although anti-dsDNA B cells are absent in the VH3H9 Tg mice, it is thought that 
this phenomenon is due to receptor editing. When the ability to edit is inhibited (RAG -/-), 
anti-dsDNA cells are centrally deleted 159. It is thought that induction of programmed cell 
death following BCR engagement is the main mechanism responsible for the elimination of 
autoreactive B cells in the BM.  
 
Peripheral Deletion 
 There is evidence that autoreactive B cells can be deleted in the periphery. This was 
first demonstrated using anti-H-2Kk,b Ig Tg mice that also express the H-2Kb molecule only 
in the liver  162. B cells in these mice were able to exit the BM and were eliminated in the 
periphery. In addition, in non-Tg mice, BCR stimulation induces program cell death in 
transitional, newly migrated B cells, suggesting that transitional B cells in the periphery 
remain sensitive to antigen-induced apoptosis 23, 24, 26, 163. Defects in transitional B cell 
signaling following BCR ligation in New Zealand black mice, result in increased Bcl-2 
expression leading to a break in tolerance and autoimmunity. Recent findings by Kumar et al. 
demonstrates how the expression of the Ly108.2 isoform derive from lupus-prone 
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NZM2410/NZW strain of mice when expressed in anergic HEL B cells (model described 
below) resulted in reduced B cell death and break in tolerance 164, 165, 166 . 
 
Anergy 
 Autoreactive B cells that are not centrally or peripherally deleted, or undergo receptor 
editing, can still be regulated by a process that renders them functionally impaired to being 
activated by antigen or TLR ligands and unable to differentiate into PCs. This state of 
unresponsiveness is described as anergy, and was originally described by Nossal et al. It is 
clear that autoreacitve B cells can be rendered anergic by multiple mechanisms and that 
functional and phenotypical differences exist between the different types of anergic B cells 
143, 167, 168, 169, 170, 171, 172.  
 Initial studies using anti-HEL B cell Tg mice, in which HEL Ag was expressed as a 
soluble protein (MD4xML5 mice) by Goodnow et al., laid the foundations for future 
understanding of B cell anergy. His work, and others that followed in the HEL model, as well 
as in other Ig-Tg B cell models, identified key features that would be used to categorize and 
determine anergic B cells. These features include inactivation or attenuation of BCR 
signaling, reduced membrane Ig expression, and reduced half-life. These features were also 
observed in the dsDNA B cell model (cells expressing λ1 or λ2 light chains associated to the 
VH3H9 heavy chain), as well as in the Ars/A1 model. In the latter model, B cells expressed 
normal levels of surface IgM, yet they had a reduced half-life and defective BCR signaling. 
Ars/A1 B cells are specific for the arsonate hapten but also cross-react with a low affinity to 
self antigen (ssDNA) 142, 143, 168, 173, 174.  
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 In contrast, other B cell models in which autoreactive B cells are functionally 
impaired and unable to secrete antibodies do not share the characteristics described for the 
anti-HEL, anti-dsDNA and Ars models. B cells in the ssDNA (VH3H9/Vκ8), anti-insulin 
and the anti-Sm (2-12H, 2-12H/Vκ8) mouse models are able to mature, have a normal half-
life, normal levels of surface IgM and are able to induce signaling following BCR 
stimulation 168, 171.  
 A recent study by Cambier’s group suggests the T3 cells described by Allman et al., 
which express CD93 (C1qRp), are in fact anergic cells and not an intermediate 
developmental stage. These T3 cells (An1, anergic population 1), share the same 
characteristics of classic anergic B cells described above. These An1 B cells are not only 
found in MD4xML5 mice, but in the Ars1/A1 and anti-dsDNA, as well as in non-Tg mice. 
Interestingly, T3 or An1 B cells are not found in the anti-insulin or anti-Sm (2-12H/Vκ8) 
mice, where B cells are also anergic 175. These differences point to alternative mechanisms 
leading to anergy. Possible factors dictating which type of anergic state is induced could be 
the affinity of the BCR, or the form of the antigen. In the particular case of the Ars1 and HEL 
models, blocking Ag binding (or adding a non-cross linking hapten) resulted in CD93 
downregulation and the ability to signal following BCR stimulation. These data suggest that 
constant antigen engagement maintains anergy in these B cells, and that anergy is reversible. 
It is not clear whether anergic B cells in other models are or are not constantly engaging Ag. 
 BCR uncoupling or desensitization has been described as another possible mechanism 
by which BCR signaling is inhibited. Constant Ag engagement by the BCR results in 
physical separation of the Igα/Igβ signaling component of the BCR from the IgM Ag binding 
component of the BCR, which consequently inhibits BCR signaling. The augmented 
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expression of negatively regulating proteins is an alternative mechanism by which BCR 
signaling is inhibited in some autoreactive B cells 176. Examples of these are CD5 and SHP-1 
177. When bred to the CD5 deficient mouse, anti-HEL B cells are able to break tolerance. 
Furthermore, SHP-1 is chronically activated in some anergic B cells (Ars1), and when it is 
deleted, these cells can become activated. SHIP-1 deletion also results in autoimmunity, 
consistent with its role in B cell tolerance 178.  
  Alterations of protein expression induced by self-antigen via the BCR can also result 
in B cell anergy without affecting BCR proximal signaling events.  These proteins play 
important roles as effectors or transcription factors required for survival, proliferation and PC 
differentiation. In the anti-insulin model, B cells are able to signal following BCR ligation, 
but do not proliferate, and subsequently die. It has been shown that NFAT expression (TF 
involved in B cell survival) in these anergic B cells is lower than in non-Tg B cells, and is not 
translocated to the nucleus following BCR signaling 170. The HEL model of anergy is another 
example of this.  Here, the overexpression of c-Myc (TF involved in proliferation and 
survival), results in B cells that are no longer anergic and are able to secrete 179. These 
examples (and others) suggest that anergy can be attained not just by modifying proximal 
events of BCR signaling but also by affecting TF involved in proliferation and survival. 
 B cell activation by microbial and viral infections can precipitate the onset of 
autoimmunity. Several studies have demonstrated that TLR engagement can lead to the 
activation of autoreactive B cells and induce Ab secretion. In addition, research has shown 
the critical role of TLRs for the onset of autoimmunity in autoimmune-prone mice 180. The 
loss of TLR9 in lupus-prone mice, for example, leads to the inhibition of anti-dsDNA and 
anti-chromatin Abs, but has no effect on the anti-Sm response. In some cases (specifically 
23
TLR9 in dsDNA), TLR activation can act simultaneously and synergize BCR activation 
resulting in a break in tolerance 181, 182, 183.  
 Interestingly, in some instances, TLR activation of anergic B cells does not result in 
Ab secretion. TLR4 and TLR9-induced activation of anergic anti-HEL B cells is blocked or 
reduced in vitro. In this particular case, chronic antigen engagement leading to high basal 
levels of phosphorylated ERK inhibits TLR induced Ab secretion 184, 185. When these cells are 
treated with ERK inhibitors, their ability to secrete Ab in response to TLR activation is 
restored, but as I will show (Chapter 4) this mechanism is not involved in regulating other 
anergic B cells.  
 Although all the mechanisms of anergy described so far involve intrinsic 
modifications most likely induced by antigen, a recent report by Vilen’s group suggests that 
extrinsic factors can help maintain autoreactive B cells in an anergic state. The report showed 
that IL-6 secreted by dendritic cells repressed anergic B cells and rendered them unable to 
respond to TLR stimulation 186. Other factors such as TNFα and CD40L play similar roles. 
This mechanism of repression would block bystander activation of autoreactive B cell during 
the course of an immune response and therefore protect from initiation of autoimmunity. 
 Overall, it is clear that multiple mechanisms result in B cell anergy. It is more likely 
that several of the mechanisms described here (among others) act jointly to inhibit activation 
of autoreactive B cells. Which factors and stimuli are responsible for inducing these 
mechanisms is still an area of important research. 
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Follicular exclusion 
 In contrast to the mechanisms of tolerance described above, autoreactive B cells can 
be eliminated in the periphery by more indirect means. First, as described in the MD4xML5 
model, anergic anti-HEL B cells that are able to form normal follicles are, however, unable to 
migrate into the follicle in the presence of competitive non-Tg B cells. They remain instead 
in the B/T interface and are quickly eliminated within a few days. For this elimination to 
occur, both non-Tg B cells and antigen are required 143, 187. The inability to enter the follicle 
is attributed to low expression of CXCR5, a chemokine receptor required for normal B cell 
migration into the follicle. It was originally argued that the inability to enter the follicle 
prevented these cells from accessing B cell survival factors within the follicle. However, 
even if anergic anti-HEL B cells are allowed to enter the follicle they are still eliminated 188. 
 One possible explanation is that with reduced numbers of self-reactive B cells, 
antigen is increased, relatively, to the number of self-reactive B cells present. HEL is now 
more readily available for the self-reactive B cells which could result in increased BCR 
occupancy and, consequently, increased BCR signaling resulting in B cell deletion. This 
hypothesis still remains to be resolved, but it has been recently demonstrated that survival 
factors are indeed involved in this process, particularly BAFF. It is thought that chronic 
antigen engagement induces Bim upregulation which would lead to apoptosis of the 
autoreactive cell. BAFF acts by preventing Bim-induced apoptosis. Evidence to support this 
hypothesis includes elevated BAFF levels in the MD4 x ML5 Tg mice as compared to non-
Tg mice. Furthermore, BAFF injection resulted in partially rescue of transferred anergic anti-
HEL B cells 189. 
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 Anergic anti-dsDNA B cells are also unable to enter the follicle when non-Tg B cells 
are present. In this case it is thought that the defect is due to the presence of regulatory T 
cells. Lack of T cell suppression as well as T cell help were required for these cells to break 
tolerance and migrate into the follicle 167, 190. More recently, FcγRIIb has been shown to be 
required for anti-DNA B cell follicular exclusion as well as maintenance of tolerance 191. 
 
E. Anti-Sm B cells (2-12H Tg) 
2-12H transgenic mouse models 
 One of the antigens that is a frequent target of the immune system in the autoimmune 
disease Systemic lupus erythematosus (SLE) is the ribonucleoprotein Sm 192, 193. Antibodies 
against Sm are also present in autoimmune MRL/lpr mice, which are used as a mouse model 
of SLE 194. The prevalence of anti-Sm positivity in these mice is of 25% 195, 196. To study the 
regulation and activation of anti-Sm B cells, a rearranged, unmutated heavy chain of a 
MRL/lpr hybridoma was used to create an Ig Tg mouse, named 2-12H 197. The 2-12 heavy 
chain has the ability to pair with a variety of light chains, and bind Sm, ssDNA, or both. 
Consistent with this, the vast majority of the 2-12H B cells have BCRs specific for Sm. 
Interestingly, antibody serum levels against Sm were not significantly different from non-Tg 
littermates. Originally, it was thought that most of the Sm binding B cells (approximately 
30%) were transitional B cells and had a short half-life, suggesting that anti-Sm B cells were 
eliminated by peripheral deletion 197. Although peripheral deletion occurs, as will be shown 
in Chapter 2, it was later determined that many of these anti-Sm B cells were mature MZ B 
cells.  
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Anti-Sm B cell activation and regulation 
 Many anti-Sm B cells from non-autoimmune 2-12H Tg mice are not normally 
activated in vivo, but when crossed to the MRL/lpr background, anti-Sm B cells are activated 
and secrete Ab 198. The 2-12H Ig transgene in this autoimmune background increases the 
prevalence and accelerates the onset of anti-Sm secretion. These results demonstrate that the 
tolerance mechanisms regulating anti-Sm B cells are either overcome or defective in this 
autoimmune setting.        
 Additional data suggests that 2-12H B cells can overcome tolerance if changes in 
BCR signaling strength occur. 2-12H Tg mice crossed to the CD19 Tg mice, in which B cells 
had higher expression of CD19, showed increased levels of anti-Sm serum. In contrast, 2-
12H CD19ko mice showed no signs of B cell activation, but had instead a population of anti-
Sm B cells with a mature phenotype 199. In another instance, 2-12H B mice deficient for 
CD22 (a negative regulator of BCR signaling) had similar characteristics to the 2-12H 
CD19Tg mice. These data suggest that changes in the BCR signaling strength can lead to 2-
12H anti-Sm B cell activation 199. One possible explanation for these observations is that 
increased CD19 levels or decreased CD22 levels result in a lower threshold of BCR 
activation, as compared to normal 2-12H B cells and that the normal level of self ag can now 
induce activation. Another possibility is that these changes had an impact on entry of the 
anti-Sm B cells into the mature B cell subsets. As an example, increased BCR signaling 
possibly led to an increase in anti-Sm MZ B cells, and as these cells are easier to activate 
than Fo B cells, this resulted in an increase in anti-Sm Ab serum levels.  
 Anti-Sm B cell activation could also occur by increasing the Ag load to a level above 
that needed to exceed the B cell activation threshold. Sm, together with other nuclear 
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antigens, is found in the surface of apoptotic cells. Injection of apoptotic cells into 2-12H Tg 
mice resulted in a transient increase in serum anti-Sm. Similarly, defects in apoptotic cell 
clearance induce an anti-Sm response. The Mer receptor is involved in the clearance of 
apoptotic cells by macrophages and the loss of function by this tyrosine kinase receptor 
results in a defect on the clearance of apoptotic bodies. An increase in serum anti-Sm Abs 
was observed when the 2-12H Ig transgene was crossed to the Mer deficient background 200. 
Data suggests that the cells activated are MZ and B1 B cells.  
 Nonetheless, anti-Sm B cells maintain tolerance in the normal background. In part, it 
is believed that some anti-Sm B cells in the 2-12H Tg mouse are anergic. Findings using the 
2-12H/Vκ8 double Tg mouse (see below) supports this hypothesis 171. Furthermore, 2-12H B 
cells express higher levels of CD5 (a negative regulator of BCR signaling) than non-Tg B 
cells (data not published). CD5 expression was shown to be important in maintaining anergy 
in the anti-HEL mouse model. In addition, it has been demonstrated by Culton et al. that a 
particular population of pre-PC cells are blocked from differentiation to PCs in the 2-12H Tg 
mouse, but not in non-Tg or 2-12H MRL/lpr mice. These CD138+ prePCs were unable to 
upregulate the BAFF receptor BCMA important for pre-PC survival and were eliminated. 
Moreover Blimp-1 was not upregulated, suggesting that regulation occurs prior to that point 
201. 
 These results taken together suggest that the affinity of the BCR for the antigen and 
the amount of antigen present can have a major impact on the maintenance of anti-Sm 
tolerance. This also suggests that there are several mechanisms of tolerance acting on these 
cells. Because 2-12H Tg mice have a variety of BCR affinities, it is difficult to completely 
address these questions. It is possible that the BCR affinity for Sm could determine which, if 
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any, mechanism of tolerance is set in place. In order to test this, the 2-12H Ig transgene has 
been crossed to light chain Tg mice. Using this strategy we can analyze anti-Sm B cell 
populations bearing the same affinity, which will vary depending on the light chain used. 
 
 Anti-Sm Double Tg mouse models 
A double transgenic mouse was generated using the 2-12H heavy chain and the Vκ8 
light chain. This combination resulted in B cells bearing a BCR with a low affinity for Sm. In 
this double Tg mouse, anti-Sm Fo B cells were present, but MZ and B1 B cells were absent. 
These cells were long lived, expressed normal levels of surface IgM but were anergic, as they 
were unable to secrete following LPS stimulation. Unexpectedly, these cells were able to 
compete with on non-Tg B cells for entry into splenic follicles 171. Although this double Tg 
model shed light on the regulation of anti-Sm B cells it represented only one clonotype and 
one affinity for Sm. Therefore, I generated a second double Tg mouse line, combining the 2-
12H transgene with a Vκ4 transgene. 2-12H/Vκ4 B cells bind to Sm with a higher affinity 
than 2-12H/Vκ8 B cells allowing me to examine the influence affinity on regulation of anti-
Sm B cells. Furthermore, 2-12H/Vκ4 Tg mice also present a mature population of MZ B 
cells which provided me the opportunity to address regulation of anti-Sm MZ B cells without 
the confounding influence of diverse clonotypes or affinities.  
In chapter 2, I present evidence arguing that high affinity anti-Sm B cells from 2-
12H/Vκ4 transgenic mice are anergic but, unlike low affinity 2-12H/Vκ8 B cells, are unable 
to compete with non-Tg B cells and are eliminated. This elimination correlates with a 
minimal responsiveness to the B cell survival factor BAFF. It there for suggests that the 
affinity of the BCR for Sm will dictate if a cell will be able to compete or will be eliminated. 
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In chapter 3, I will show evidence that the BCRs of 2-12H and 2-12H/Vκ4 anti-Sm 
Fo B cells signaling competent. Nonetheless these cells undergo rapid cell death unable to 
proliferate. This defect correlates with an imbalance in pro and anti-apoptotic proteins. 
However, while 2-12H MZ B cells signaled efficiently in response to BCR ligation, 2-
12H/Vκ4 MZ B cells are defective. They also show no sign of in vivo activation which lead 
me to conclude that 2-12H/Vκ4 MZ B cells are anergic while 2-12H MZ are not, and are 
regulated by BCR uncoupling. 
I also assessed the ability of these cells to respond to TLR stimulation. Anti-Sm B 
cells are able to proliferate but are however defective in antibody secretion. I demonstrate in 
chapter 4 that the antibody secretion defect observe regulated by a combination of activation-
induced cell death and a block in PC differentiation, which is dependent on the B cell subset 
identity. Furthermore, 2-12H/Vκ4 B cells display the highest degree of regulation, compared 
to 2-12H B cells, suggesting once again that the BCR affinity is able to influence the degree 
of regulation. These mechanisms are ERK-independent which suggests the existence of an 
ERK-independent pathway in the regulation of PC differentiation by anergic B cells 
contrasting the anergic anti-HEL B cells observations. 
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CHAPTER 2 
Regulation of anergic anti-Sm B cells by decreased 
responsiveness to the B cell survival factor BAFF 
 
ABSTRACT 
 Anergy is an important mechanism for the regulation of autoreactive B cells. In the 
presence of naïve B cells, anergic B cells of some specificities are unable to enter the follicle 
and undergo rapid cell death due to a requirement for higher than normal concentrations of 
the survival factor BAFF.  Previous analysis of low affinity anti-Sm B cells from 2-12H/Vκ8 
transgenic mice differ from this paradigm.  Low affinity anti-Sm B cells are neither blocked 
from entry into the follicle, nor short-lived even in the presence of competitor non-
autoreactive B cells. I hypothesize that the BCR affinity for self-antigen influences the 
mechanisms regulating survival and competition abilities of anti-Sm B cells. Herein I present 
evidence that high affinity anti-Sm B cells from 2-12H/Vκ4 transgenic mice are also 
divergent from this paradigm, and are regulated differently than low affinity anti-Sm B cells. 
2-12H/Vκ4 B cells belong to the follicular (Fo), marginal zone (MZ), and B-1 subsets.  Like 
low affinity anti-Sm B cells, high affinity anti-Sm Fo and MZ B cells are non-responsive to 
toll-like receptor (TLR) activation and thus anergic.  They can enter the follicle, even in the 
presence of competition, likely due to elevated CXCR5 levels.  However, unlike low affinity 
anti-Sm B cells, high affinity anti-Sm B cells are eliminated from the B cell repertoire in the 
presence of competitor B cells, which correlates with a minimal responsiveness to the B cell 
survival factor BAFF. Thus, affinity for Sm determines the responsiveness to a key B cell 
survival factor.   
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INTRODUCTION 
The regulation of autoreactive cells is paramount to prevent the development of 
autoimmune diseases. Multiple mechanisms of tolerance have been described, which ensure 
that autoreactive B cells are inhibited from reaching maturity or/and differentiating to plasma 
cells (PCs). These mechanisms include receptor editing and central deletion in the BM 1, 2, 3, 4. 
Autoreactive B cells that can escape to the periphery are subject to regulation by peripheral 
deletion and anergy 3, 5, 6. Which mechanism is employed to regulate the autoreactive B cells 
of any given specificity is not fully understood, but is influenced by multiple factors, 
including the form and amount of Ag, when antigen is encountered, and BCR affinity.  
 Immunoglobulin transgenic mouse models have been powerful tools for 
understanding the mechanisms of B cell anergy 3, 7. In the case of anergic anti-HEL B cells, 
these cells are normally arrested from development to mature Fo or MZ B cells, express low 
levels of membrane IgM and have a short half-life. Other models, including the anti-dsDNA 
and the Ars/A1 models, display similar characteristics 8, 9, 10. It has been recently determined 
that transitional 3 (T3) B cells also share these characteristics and therefore it is thought that 
they are anergic cells in non-transgenic mice 11. However, not all anergic B cells share these 
characteristics. For example, anti-ssDNA and anti-insulin B cells differentiate to mature Fo 
and MZ B cell, have normal half-lives and express normal BCR levels, but are nevertheless 
defective in PC differentiation 12, 13, 14. It is therefore important to understand what causes 
these differences and whether the mechanisms of anergy differ among autoreactive B cells 
that exhibit these various anergic phenotypes.    
Anergic B cells are refractive to activation, but because they persist in the repertoire, 
they could escape tolerance leading to autoimmunity. In the presence of non-Tg B cells, anti-
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HEL and anti-dsDNA anergic B cells are concentrated at the B/T interface 12, 15, 16. Anti-HEL 
are eliminated faster due to an increased requirement for BAFF 17, 18. BAFF a TNF family 
member, is required for B cell survival and maturation 19, 20, 21, 22, 23, 24.  It provides a key 
survival signal through its ability to downregulate the pro-apoptotic protein Bim and by 
upregulate the pro-survival factor Mcl-1 22. Thus, in addition to defects in ability to respond 
to activating signals, anergic B cells are highly susceptible to elimination from the normal B 
cell repertoire through defects in the ability to respond to critical survival signals.   
 We have previously described the anti-Smith (Sm) 2-12H Tg mice. Sm is a 
ribonucleoprotein targeted by the immune system in systemic lupus erythematosus. In these 
mice, 30-50 % of B cells bind Sm and are mature Fo, MZ, and B-1 B cells 25. Despite the 
large number of anti-Sm B cells, serum anti-Sm levels are not different from those in non-Tg 
mice.  Multiple regulatory mechanisms contribute to anti-Sm B cell tolerance. 2-12H bearing 
B cells can express diverse light chain genes, generating B cells with a wide range of Sm 
binding abilities and likely accounts for their presence as Fo, MZ and B-1 B cells. This range 
of Sm binding ability generates anti-Sm B cells that are likely to be regulated differently.  2-
12H Tg mice have a higher turn over rate compared to wild-type mice, suggesting that some 
anti-Sm B cells are peripherally eliminated 25.  Some anti-Sm B cells are activated to a pre-
plasma cell stage before quickly being eliminated and others are regulated by anergy 26.  
Anergy was demonstrated by using 2-12H mice that carry a Vκ8 L chain transgene and 
produce low affinity anti-Sm B cells 27. Anergy is maintained by B cell intrinsic and extrinsic 
mechanisms. Thus, while these cells are intrinsically poor responders to LPS, chronic antigen 
engagement has reprogrammed their response to the pro-differentiation cytokines, IL-6, 
CD40L, and TNFα repress further LPS responsiveness 28.   
49
 To determine whether anti-Sm B cells of higher affinity are similarly regulated, we 
generated an anti-Sm B cell model that generates B cells of higher affinity than our 
previously described 2-12H/Vκ8 Tg mice. These mice carry the 2-12H transgene along with 
a Vκ4 transgene. Although 2-12H/Vκ4 B cells are anergic, they differ from low affinity 2-
12H/Vκ8 B cells in that, while low affinity B cells are limited to differentiation to the Fo B 
cell stage, high affinity anti-Sm B cells differentiate to multiple B cell subsets.  In addition, 
high and low affinity anti-Sm B cells differ in ability to compete with non-autoimmune B 
cells for survival; the latter are effective competitors and have a long half-life even in the 
presence of a majority of non-autoreactive B cells, whereas the former are not competitive 
and are eliminated in the presence of competitor non-autoreactive B cells.  The inability of 
high affinity anti-Sm B cells to compete for survival is not due to an inability to enter B cell 
follicles, but is likely due to a minimal responsiveness to BAFF. These data suggest that 
BCR affinity determines the competitive ability of autoreactive B cells regulating 
responsiveness to BAFF.  
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MATERIALS AND METHODS 
Mice 
Anti-Sm 2-12H Tg mice and Vκ4 Tg mice have been described previously 29, 30. 2-12H/Vκ4 
double Tg mice were generated by crossing 2-12H with Vκ4 Tg mice. 2-12H Tg mice are on 
a mixed background of C57BL/6 and CB17. Vκ4 Tg mice are on the CB17 background. 2-
12H/Vκ4 Cκ-/- double Tg mice were also generated to confirm allelic exclusion. No 
phenotypic or functional differences were observed between the 2-12H/Vκ4 and the 2-
12H/Vκ4 Cκ-/- double Tg mice. Offspring carrying transgenes were identified by tail 
genomic DNA as described previously 25. All animal protocols were approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
 
Flow Cytometry 
Single-cell suspensions of splenocytes were prepared and RBCs were lysed using an RBC 
lysis solution (1 M Tris, 0.15 M ammonium chloride, and 0.1 M EDTA). All staining was 
done in RPMI 1640 medium (HyClone) containing 2.0% bovine calf serum (HyClone) as 
previously described (Qian). FcRs were blocked with mAb 2.4G2 for 15 min at 4°C. Cells 
were analyzed at the University of North Carolina Flow Cytometry Facility (Chapel Hill, 
NC) using a FACSCalibur (BD Biosciences) or CyAn (Dako). Analysis was performed using 
Summit software (Dako). The Abs specific for IgM, IgMa, B220, CD21, CD23, CD9, CD1d 
and CXCR5 were obtained from BD Biosciences. These Abs were biotinylated or conjugated 
to allophycocyanin, PE, FITC, PE-Cy7, APC-Cy7, or PerCP. For the identification of anti-
Sm B cells we used Sm (SMA-3000; Immunovision, Springdale, AR) that was biotinylated 
in our laboratory as described previously (Santulli-Marotto). BAFF receptors were detected 
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using anti-TACI (TNFRSF13B), anti-BAFF R (TNFRSF13C) and anti-BCMA (TNFRSF17) 
from R&D Systems.  
 
BrdU labeling 
Mice were given 0.5 mg/ml 5-bromo-2_-deoxyuridine (BrdU; Sigma-Aldrich, St. Louis, 
MO) with 1 mg/ml dextrose in their drinking water continuously for 4 wk. At different time 
points mice were sacrificed and spleens cells were prepared for flow cytometry as described 
above. Staining for BrdU was done as described previously using anti-BrdU-FITC (BD 
Biosciences) 27, 31. 
 
Cell purification 
Splenic B cells were isolated by negative selection using IMagTM Streptavidin Particles Plus 
(BD Biosciences) following manufacturers protocol for magnetic labeling and separation. 
Cells were incubated for 40 min with a cocktail of biotinylated antibodies (anti-CD3, anti-
CD4, anti-CD8, anti-CD11c, anti-CD11b and anti-CD49b (BD Biosciences)). Cells were 
washed thoroughly and incubated with Streptavidin DM particles and then separated via 
magnet.  B cells were 92–98% pure as determined by flow cytometry.  
 
Stimulation 
Purified B cells were (1x106/ml) were cultured in 24 well plates in complete RPMI 
containing 10% FCS, L-glutamine, penicillin, streptomycin, and 2-mercaptoethanol. Cells 
were stimulated with 10 µg/ml LPS or 1 µg/ml CpG (InvivoGen) for 5 days. rIL-6 was added 
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at day 0 as described previously 28. Supernatants were collected and Ab secretion determined 
by ELISA. 
For BAFF survival assay, B cells were cultured as described above and stimulated 
with indicated amounts of recombinant BAFF (PeproTech 310-13). To determine 
spontaneous cell death purified B cells were cultured in complete RPMI for the indicated 
times. Cell death was determined by flow cytometry staining cells with either 7AAD (BD 
Biosciences) or LIVE/DEAD dead cell stain kit (Probes-Invitrogen).  
 
ELISAs 
Quantitation of anti-Sm Abs, total IgM and IgMa in mouse serum and supernatants was done 
by ELISA as previously described 25. For anti-Sm Ab detection 96-well flat-bottom 
polyvinylchloride plates were coated with Sm protein (Immunovision) over night in borate-
buffered saline. All washes were performed with borate-buffered saline. Plates were blocked 
with borate-buffered saline, 0.5% BSA, and 0.4% Tween 80 for a minimum of 1 h before 
adding the samples. All samples were analyzed in triplicate. To develop the assays we used 
either goat anti-mouse IgM-alkaline phosphatase (AP; Southern Biotechnology) or anti-
IgMa-biotin followed by streptavidin-AP (BD Biosciences). IgM was quantitated by adding 
sera or supernatant to plates coated with polyclonal goat anti-mouse IgM (Southern 
Biotechnology) and detected with either biotinylated anti-IgMa or anti-IgMb (BD 
Biosciences), followed by streptavidin-alkaline phosphatase (Southern Biotechnology). 
Assays were developed with 1 mg/ml p-nitrophenyl phosphate (Sigma, St. Louis, MI) in 0.01 
M diethanolamine and the OD405 determined. Purified mouse IgMa (TEPC 183; Sigma-
Aldrich) was used as a standard for total IgM and IgMa ELISAs. 
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BM Chimeras  
Hematopoietic stem cells from 2- to 3-mo-old 2-12H/Vκ4 Tg mice and non-Tg littermates 
were isolated as described previously 27, 32.Hemopoietic stem cells, which exclude the 
Hoechst dye, were sorted using a MoFLo high speed sorter (Cytomation). Sorted cells from 
both strains were mixed in a 1 to 1 ratio in PBS and were injected via tail vein into non-Tg 
littermate mice that had been lethally irradiated (2 doses of 500 rads 4hs apart) 24 h 
previously. Analysis of recipients was performed at least 3 months after reconstitution. To 
determine the degree of chimerism, BM cells were stained to determine the ratio of immature 
(CD21-, CD23-, IgM+) IgMa vs IgMb B cells. 
 
Adoptive Transfer  
Approximately 5 X 106 purified splenic B cells from both 2-12H/Vκ4 Tg and non-Tg mice 
were labeled with CFSE (Molecular Probes) and transferred i.v. into non-Tg littermate mice. 
Spleen cells were analyzed by flow cytometry 3 and 7 days after transfer. CFSE positive cells 
were assessed for IgMa or IgMb (2-12H/Vκ4 or non-Tg) expression to determine cell 
numbers.  
For immunofluorescence, 1 x 107 purified splenic 2-12H/Vκ4 B cells were transferred i.v 
into non-Tg littermate mice.  
Immunofluorescence 
Freshly isolated spleens were embedded in Tissue-Tek OCT (Sakura Finetek) and snap 
frozen. Six-micrometer spleen sections were prepared and fixed for 5 min in acetone:MeOH 
at -20°C before staining. Sections were blocked for 1 h with Superblock 
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Blocking buffer in PBS (1:1 ratio) containing 2.4G2 anti-FcR Ab. Slides were rinsed and 
stained at room temperature for 2hs with anti-CD3-PE, anti-B220-APC and anti-IgMa-biotin 
(BD Biosciences) diluted in blocking buffer. IgMa staining was revealed by 
streptavidin Alexa 488 (Molecular Probes). Stained slides were rinsed with PBS and 
coverslips mounted in FluorSave mounting media (Calbiochem). Analysis was performed 
using a digital deconvolusion microscope (Intelligent Imaging Innovations (3I)). Images 
were collected and analyzed usingSlidebook software (3I). 
 
Statistical analysis 
The Student t test was used to assess the significance of the differences between groups. A 
value of p< 0.05 was considered significant. 
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RESULTS 
2-12H/Vκ4 anti-Sm B cells are better Sm binders, generate all B cell subtypes and are long 
lived 
To determine how affinity for Sm affects the regulation of anti-Sm B cells, we 
combined the 2-12H transgene with a Vκ4 transgene (Fig 1A-B).  The relative Sm binding 
ability of 2-12H/Vκ4 Tg B cells was compared to 2-12H and 2-12H/Vκ8 anti-Sm B cells by 
calculating the ratio of the anti-Sm to IgM mean fluorescence intensities (Fig. 1B).  2-
12H/Vκ4 B cells had the highest ratio, which suggests the 2-12H/Vκ4 BCR possesses a 
higher affinity for Sm. The potential of 2-12H/Vκ4 B cells to differentiate into different B 
cell subtypes was assessed by flow cytometry.  Cells were gated on B220+ IgM+ B cells. In 
addition to transitional (Tr) B cells (CD23- CD21-), 2-12H/Vκ4 mice also had mature 
follicular (Fo) B cells (CD23+ CD21+) and a significant population (~12 %) of marginal zone 
(MZ) B cells (CD23+/- CD21high), which also expressed CD9 and higher levels of CD1d (Fig. 
1A and data not shown). This contrasts with 2-12H/Vκ8 mice in which MZ B cells were 
essentially absent, but was similar to 2-12H Tg mice 27.  The number of Fo, MZ and Tr B 
cells were similar between 2-12H and 2-12H/Vκ4 mice, but the number of Fo B cells was 
about half of that in non-Tg mice (Fig. 1C). Analysis of peritoneal cells showed that 2-
12H/Vκ4 mice also generated B1 B cells based on a phenotype of CD5+ CD23- and CD11b+ 
(data not shown). 
To determine whether 2-12H/Vκ4 B cells were regulated to prevent spontaneous 
activation, we assessed IgMa and anti-Sm antibody levels in serum. Total serum IgM levels 
were similar in 2-12H/Vκ4 and 2-12H mice, but significantly lower than in non-Tg mice. 
IgMa levels were lower than in 2-12H Tg mice, but their anti-Sm IgMa levels were similar 
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(~2ug/ml).  Thus, 2-12H/Vκ4 B cells have not differentiated to antibody secreting cells 
(ASCs).  
 Autoreactive B cell turnover rates are often shorter than those of non-autoreactive B 
cells, and therefore, we determined the turnover rate of 2-12H/Vκ4 B cells by BrdU 
incorporation 33. As previously reported, 2-12H mature B cells showed a significantly higher 
turnover rate than non-Tg mature B cells. Surprisingly, the turnover rate of 2-12H/Vκ4 
mature B cells was no different than that of control non-Tg B cells, which would suggest that 
high Sm-binding B cells are not peripherally deleted in the absence of competition (Fig 1E). 
Thus, 2-12H/Vκ4 B cells, despite expressing a monoclonal BCR, differentiate to all B cell 
subsets, are not spontaneously activated, and have a normal half-life.  
 
2-12H/Vκ4 anti-Sm B cells are anergic 
To assess the functionality of 2-12H/Vκ4 anti-Sm B cells, we determined their ability 
to become ASCs following LPS and CpG stimulation. Purified B cells were stimulated in 
vitro for 6 days and IgM secretion levels in the supernatant measured by ELISA. As seen in 
Fig. 2A, 2-12H/Vκ4 B cells showed a marked reduction in ability to secrete Ab following 
LPS stimulation compared to non-Tg B cells, secreting on average 78% less than the control 
cells. 2-12H B cells showed a lesser degree of regulation and secreted on average 38% less 
than control B cells. Similar defect in Ab secretion were observed following CpG stimulation 
Fig 2B. 2-12H and 2-12H/Vκ4 B cells secreted on average 46% and 58% less than control 
respectively. Thus, 2-12H/Vκ4, and to a lesser degree, 2-12H anti-Sm B cells are hypo-
responsive to mitogenic stimulation, indicating functionally non-responsivness (anergy). 
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We recently showed that IL-6 represses LPS-induced Ab secretion by 2-12H/Vκ8 
anti-Sm B cells and other autoreactive B cells, but not naïve B cells 28. To determine whether 
higher affinity anti-Sm B cells are also repressed by IL-6, 2-12H/Vκ4 B cells were 
stimulated with LPS in the presence or absence of IL-6, and antibody (Ab) secretion 
measured by ELISA.  As shown in Fig. 2C, IL-6 reduced Ab secretion by ~60% compared to 
the untreated LPS stimulated cells. Thus, as with low affinity anti-Sm B cells, IL-6 represses 
the activation of the higher affinity 2-12H/Vκ4 B cells.   
 
Competition with non-Tg B cells regulates high Sm binding 2-12H/Vκ4 B cells survival. 
 Autoreactive B cells can be regulated by competition for survival factors with non-
autoreactive B cells.  In an environment that contains a majority of non-autoreactive B cells, 
anti-HEL B cells are unable to access BAFF, a potent B cell survival factor required for B 
cell survival in the periphery, and consequently have a shorter half-life than when in a 
monoclonal anti-HEL B cell environment 15, 16.  Surprisingly, low affinity 2-12H/Vκ8 anti-
Sm B cells were unaffected by the presence of a majority of non-Tg B cells 27. To determine 
whether high affinity anti-Sm B cells are competitively disadvantaged, we generated bone 
marrow chimeras and performed B cell transfers into non-Tg littermates. 
 To create bone marrow chimera mice, hematopoietic stem cells were sorted from 
bone marrow of non-Tg and 2-12H/Vκ4 mice as previously described  27, 32.  Cells from mice 
of the two strains were mixed at a 1:1 ratio and injected i.v. into lethally irradiated non-Tg 
littermates.  Control mice were injected with non-Tg or 2-12H/Vκ4 stem cells or received no 
cells. Three months later, we analyzed 4 chimeric mice. To establish the degree of 
chimerism, the ratio of immature (B220+IgM+CD21-) IgMb (non-Tg) vs IgMa (2-12H/Vκ4) 
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expressing B cells in the bone marrow was determined by flow cytometry. As shown in Fig. 
3A (left panel) the ratio of IgMa/IgMb immature B cells was approximately one, reflecting 
the input stem cell ratio. However, the IgMb:IgMa ratio was markedly higher in among 
mature B cells in the spleen, averaging ~8 fold.  Control mice that received non-mixed stem 
cells had normal numbers of splenic B cells (either IgMa or IgMb) (data not shown). The 
majority of 2-12H/Vκ4 B cells in the chimera spleen were mature Fo mature B cells 
indicating that the anti-Sm B cells that populated the spleen were able to mature. Thus, high 
affinity anti-Sm B cells are unable to compete with non-Tg B cells and are presumably 
eliminated. 
 Splenic B cell transfers into non-irradiated non-Tg littermates confirmed the non-
competitiveness of 2-12H/Vκ4 B cells.  Purified non-Tg and 2-12H/Vκ4 B cells were mixed 
at a 1:1 ratio, labeled with CFSE, and transferred i.v. into non-Tg littermates. The spleens 
were analyzed 3 and 7 days later. Spleen cells were stained with anti-B220 and IgMa. CFSE 
cells were gated and IgMa B cell numbers determined, as shown in Fig. 3B.  As expected, 
fewer non-Tg B cells were seen in the spleen at day 3 than were transferred, due either to 
elimination or to trafficking to sites other than the spleen.  However, the numbers of non-Tg 
B cells remained high at day 7. In contrast, the number of 2-12H/Vκ4 B cells present in the 
spleen at day 3 was significantly lower than seen for non-Tg B cells, and the number 
decreased significantly by day 7.  The difference in cell number was not due to cell division 
of non-Tg B cells after transfer, since there was no dilution of CFSE in B cells of either 
population at day 3 or day 7 (data not shown).  Taken together, the B cell transfer and bone 
marrow chimera experiments show that in contrast to low affinity anti-Sm B cells, high Sm 
binding 2-12H/Vκ4 B cells are not competitive in a polyclonal environment.  
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2-12H/Vk4 B cells were not follicularly excluded. 
 Anergic B cells of other specificities, such as anti-HEL and anti-dsDNA B cells, are 
similarly defective in survival in the presence of a normal non-Tg repertoire 9, 12. This defect 
correlated with an inability to access B cells follicles and therefore these cells were found at 
the T/B boundary due to a decrease in CXCR5 expression, a chemokine responsible for B 
cell migration into the follicle. To determine whether 2-12H/Vκ4 B cells were similarly 
regulated, we measured CXCR5 expression levels. High affinity anti-Sm B cells expressed 
normal to high levels of CXCR5 as compared to non-Tg B cells (Fig. 4A). This was seen on 
both Fo and MZ B cells. Although expression levels were normal, it is possible that the 
receptors were not functional, or that other receptors could still impede the migration of 2-
12H/Vκ4 B cells to the follicles. Therefore, 1x107 2-12H/Vκ4 B cells were transferred i.v. 
into non-Tg littermates and their ability to enter B cell follicles by immunohistochemistry. As 
shown in Fig. 4B, 24 hours after transfer 2-12H/Vκ4 B cells were distributed throughout the 
follicles. Thus, the inability to compete with non-autoreactive B cells is independent of the 
ability to access B cell follicles.   
 
2-12H/Vκ4 anti-Sm B cells are defective in BAFF-mediated cell survival. 
 To investigate the mechanism for the non-competitiveness of 2-12H/Vκ4 B cells, we 
assessed spontaneous cell death in the absence of any stimuli in vitro. As shown in Fig. 5A, 
anti-Sm B cells from either 2-12H or 2-12H/Vκ4 mice died significantly faster than non-Tg 
B cells, and 2-12H/Vκ4 more so than 2-12H B cells. Thus, in the absence of any stimuli, 
anti-Sm B cells undergo accelerated cell death. 
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Since BAFF plays an important role in B cell survival and anergic anti-HEL B cells 
require greater amounts of BAFF to survive, we tested the ability of 2-12H/Vκ4 B cells to be 
rescued by BAFF in vitro.  2-12H/Vκ4, 2-12H, and non-Tg splenic B cells were cultured in 
increasing amounts of BAFF for 72hs and the percentage of live cells determined. Both 2-
12H and 2-12H/Vκ4 B cells showed partial rescue compared to unstimulated cells, but their 
survival rates were still significantly lower than non-Tg B cells (Fig. 5B). 2-12H/Vκ4 B cells 
displayed the highest death rate, with only an average of 15% of the cells surviving at 3 days, 
compared to 60% and 30% for non-Tg and 2-12H B cells, respectively.  Thus anti-Sm B cells 
are responding poorly to BAFF, which is not overcome by increased BAFF levels. 
 
2-12H/Vκ4 anti-Sm B cells are defective in BAFF signaling.  
The inability to survive following BAFF stimulation could be due to a defect BAFF 
receptor expression. We determined the expression pattern of the three known BAFF 
receptors in anti-Sm B cells, BAFF-R, TACI, and BCMA (Fig. 5C). The expression level of 
BAFF-R was elevated on 2-12H and 2-12H/Vκ4 Fo B cells and more so on MZ B cells 
compared to the corresponding B cells of non-Tg mice.  On the other hand, in comparison to 
non-Tg B cells TACI levels were significantly reduced on 2-12H and 2-12H/Vκ4 Fo and MZ 
B cells.  No expression difference in BCMA was observed between non-Tg and 2-12H and 2-
12H/Vκ4 B cells of either subset. Thus, 2-12H/Vκ4 anti-Sm B cells express normal or 
slightly higher levels of BAFF-R and lower than normal TACI levels suggesting that the 
minimal response to BAFF is not due to a defect in receptor expression, pointing to a defect 
in BAFF signaling.  
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DISCUSSION 
 Previous and current findings show that high and low affinity anti-Sm B cells are 
outwardly normal.  In the absence of competition they show no sign of central deletion or 
developmental arrest, have a normal turn-over rate, express normal levels of surface IgM, 
and differentiate to a mature B cell stage, high affinity to Fo, MZ, and peritoneal B-1, and 
low affinity to Fo (Fig. 1 and data not shown) 27.  Neither high nor low affinity B cells exhibit 
evidence of receptor editing based on the lack of lambda expressing B cells (data not shown).  
Nevertheless, they are anergic, indicated by an inability to secrete antibody in response to 
LPS or CpG (Fig. 2A).   
The ability of anti-Sm B cells to differentiate to a mature B cell stage and remain 
anergic contrasts with anergic anti-HEL B cells.  Anergic anti-HEL B cells normally arrest at 
the transitional 2 and 3 stage and undergo cell death 11.  However, Oliver et al. have shown 
that if cell death is blocked by a deficiency in the pro-apoptotic protein Bim, differentiation 
to the Fo B cell stage occurs and anergy is abrogated suggesting an association between the 
ability to reach the mature B cell stage and loss of anergy 34.  The analysis of 2-12H/Vκ8 and 
2-12H/Vκ4 B cells indicates that differentiation to a mature B cell stage and anergy are 
separately regulated rather than causal. The differences between the tolerizing antigens in 
these two systems are substantial and likely contribute to the differences in association of 
anergy and maturation.  For example, HEL is a soluble protein antigen, whereas Sm is 
present on the outer leaflet of the plasma membranes of apoptotic cells, which would 
increase the avidity of the BCR/Ag interaction 35.  In addition, Sm is a component of a 
ribonucleoprotein that contains RNA, a potential ligand for TLR7. In fact, TLR7 is required 
for spontaneous development of an anti-Sm response in autoimmune mice 36, 37.  Thus, in 
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addition to chronic BCR signals, anti-Sm B cells may receive chronic TLR signals, which 
may have a different outcome on the mechanism of tolerance than a chronic BCR signal 
alone.  Crosstalk between the BCR and TLR signaling pathways occurs, since chronic BCR 
signaling abrogates TLR responsiveness through an ERK-mediated molecular switch 38.  
However, the reciprocal has not been tested, and thus it will be of interest to determine the 
effect of chronic TLR signaling on tolerance induction.  
Despite differentiation to a mature B cell, high affinity anti-Sm B cells are not 
competitive with non-Tg B cells for survival in vivo.  The competitive loss of 2-12H/Vκ4 B 
cells occurs in the spleen, since non-Tg and 2-12H/Vκ4 B cell numbers are equal in bone 
marrow chimeric mice (Fig. 3).  The few splenic 2-12H/Vκ4 B cells present in the bone 
marrow chimeras are Fo mature B cells suggesting that the competitive loss occurs at a 
mature B cell stage. Thus, as with anergy induction, differentiation to a mature B cell and 
competitive elimination are controlled separately. Studies of the mechanism of competitive 
elimination for anergic anti-HEL B cells have revealed that the B cell maturation and 
survival factor BAFF is limiting for anergic B cells, and is responsible for their competitive 
elimination.  Anergic anti-HEL B cells require higher BAFF levels for survival and thus 
when cell numbers are low, as in anergic anti-HEL transgenic model, the amount of BAFF 
per anergic anti-HEL B cell is sufficient for survival.  However, when the number of B cells 
is high, as in chimeric mice, the amount of BAFF per B cell is lower and below the threshold 
for anergic B cell survival 17, 18. A similar mechanism may underlie the competitive 
elimination of 2-12H/Vκ4 anti-Sm B cells.  However, that 2-12H/Vκ4 B cells are largely 
minimal response to BAFF in an in vitro survival assay seemingly contradicts this 
explanation. The percentage of surviving 2-12H/Vκ4 B cells in the presence of BAFF does 
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not increase beyond 15-20%, even at concentrations as high as 900 ng/ml.  In contrast, anti-
HEL B cell survival reaches 50-60% survival with just 100 ng/ml of BAFF.  Thus, BAFF 
may not be the limiting factor for 2-12H/Vκ4 survival, since even high BAFF concentrations 
may be insufficient to restore in vivo survival.  Although we cannot exclude that the small 
survival advantage afforded by BAFF may be sufficient to ensure a normal life span to 2-
12H/Vκ4 B cells, anti-HEL B cells, which are more responsive to BAFF in vitro, have only a 
half-life of one-week.  Thus, another factor may control 2-12H/Vκ4 B cell competitiveness. 
One major difference between the HEL and the Sm models is the form of the antigen. While 
HEL is in a soluble form Sm is most likely found on the surface of apoptotic cells or 
phagocytosing cells. This difference could result in a continuous binding of antigen by HEL 
B cells while anti-Sm B cells might have sporadic encounters Sm rather than continuous 
interaction. Another difference between HEL and Sm autoantigens that may be relevant in 
this regard is the association of the Sm autoantigen with TLR ligands.  Thus, anti-Sm B cells 
may receive chronic TLR signaling, which could inhibit the BAFF survival pathway.   
The ability of 2-12H/Vκ4 B cells to become mature Fo and MZ B cells, whether 
subject to competition or not, implies a responsiveness to BAFF.  BAFF is required for Fo 
and MZ B cell differentiation, and B cell differentiation arrests at a transitional stage in 
BAFF-deficient mice. Thus, 2-12H/Vκ4 B cells must be competent to receive BAFF 
differentiation signals. Oliver et al. originally demonstrated independent regulation of BAFF-
induced differentiation and survival and that B cells are more sensitive to BAFF for 
differentiation than for survival 34. Thus, our findings with 2-12H/Vκ4 B cells predicts that 
the defect in BAFF responsiveness is with only the survival pathway, such as the Akt and 
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Pim2 pathways leading to upregulation of the anti-apoptotic protein Mcl-1  and the NF-κB 
activation pathway 22, 39, 40. We are currently testing these possibilities.   
Despite the anergy and competitive elimination of anti-Sm B cells, high affinity anti-
Sm cells, like low affinity anti-Sm B cells, are not excluded from entry into the follicle 27. 
Follicular entry of these cells is likely due to high CXCR5 expression, the receptor for the 
follicular chemokine CXCL13/BLC that is present in follicles and important for B cell 
retention in the follicle 41, 42.  We observed no change in CCR7 levels (data not shown), the 
receptor for CCL19/ELC and CCL21/SLC expressed in T cell areas. Changes in the relative 
levels of these two chemokine receptors are responsible for B cell migration to the T cell area 
following antigen stimulation 43. Within hours of stimulation CCR7 levels increase leading to 
the B cell migration toward T cell areas, even without a concurrent decrease in CXCR5 
levels.  A shift in the balance of CXCR5 and CCR7 expression is responsible for the 
follicular exclusion of anergic anti-HEL B cells 16, although in contrast to 2-12H/Vκ4 B cells, 
by a decrease in CXCR5 expression leading to their retention at the T-B boundary  
Overall, our findings reveal multi-layered regulation of anti-Sm B cells.  First, 
affinity for Sm is a determining factor, which must be between that of the 2-12H/Vκ8 BCR 
and below that of the 2-1H/Vκ4 BCR.  Second, B cells above a certain threshold are 
competitively eliminated before becoming mature B cells, and third, above an affinity 
threshold they are regulated by anergy. That some high affinity anti-Sm B cells escape 
competitive elimination in the bone marrow chimeric mice and differentiate to the mature Fo 
B cell stage highlights the importance of redundancy in the regulation of high affinity anti-
Sm B cells.  An important aspect of the anergy of 2-12H/Vκ4 B cells is that they are not 
activated by either LPS or CpG and are repressed by IL-6 produced by dendritic cells or 
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macrophages (Fig. 2).  Thus, recruitment into a compartment with greater exposure to these 
TLR ligands will not result in inappropriate activation.   
The findings reported here indicate that B cells specific for a self-antigen targeted in 
mouse and human SLE are regulated by a form of anergy different in multiple respects from 
that exhibited to neo-self antigens such as HEL. These differences likely reflect important 
differences in the nature and concentration of antigen pointing to the importance of 
understanding the complex interplay of signals through multiple receptors on the B cell, 
particularly BCR, BAFF-R, and TLRs, given the importance of both BAFF and TLR 
signaling to B cell autoimmunity  44, 45.   
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Figure 1. Phonotypical and functional analysis of splenic anti-Sm B cells from 2-12H and 2-
12H/Vκ4 mice.  
A, Flow cytometry analysis of splenic anti-Sm B cells subsets. Cells were gated using 
expression of CD21 and CD23 to define T1, FO, and MZ B cells as indicated in the top row. 
B, Relative BCR affinity assessment between the 2-12H, 2-12H/Vκ8 and 2-12H/Vκ4 anti-
Sm B cells. C, Splenic B cell numbers were determined by flow cytometry for the mice 
indicated. All mice were 2–5 mo of age (n=9). D, Analysis of IgM and transgene-encoded 
Abs in the sera of anti-Sm B cells by ELISA. Total IgM, left, total IgMa middle and total 
anti-Sm IgMa (n=6 each). E, Mature Fo Anti-Sm B cell half-life was calculated by BrdU 
incorporation. * Significant difference ( p<0.05), ** (p<0.01) and *** (p<0.001). 
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Figure 2. 2-12H/Vκ4 anti-Sm B cells are unresponsive to TLR stimulation and repressed by 
IL-6.  
A, Purified B cells were stimulated in vitro with 10µg/ml LPS for 6 days, and supernatants 
were analyzed by ELISA for total IgM.  B, same as A, using 1µg/ml CpG. C, Purified B cells 
were stimulated with LPS in the presence or absence of rIL-6. IgM secretion was determined 
by ELISA. * Significant difference ( p<0.05), ** (p<0.01) and *** (p<0.001). 
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Figure 3. Anti-Sm 2-12H/Vκ4 B cells are poor competitors in the presence of non-Tg B 
cells.  
A, BM chimeras were analyzed by flow cytometry. Left panel Degree of chimerism obtained 
in the BM of the chimeric mice. Cells were gated on CD21- IgM+ to determine the 
percentage of newly formed immature B cells derived from each strain. Right panel P 
percentage of IgMa (2-12H/Vκ4) or IgMb (non-Tg) B cells present in the spleen (n=4). B, 
Purified 2-12H/Vκ4 and non-Tg B cells were labeled with CFSE, mixed together and 
transferred into non-Tg littermates. 3 and 7 days later number of B cells remaining were 
calculated to determine loss of cells. 
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Figure 4. Anti-Sm 2-12H/Vκ4 B cells are not excluded from the follicle and express higher 
levels of CXCR5 than control B cells.  
A, Flow cytometric analysis of CXCR5 expression on Fo and MZ B cells. B, 2-12H/Vκ4 B 
cells were purified and transferred into control littermates to determine their ability to enter 
the B cell follicle in the presence of competitor B cells. Blue (B220-APC), Red (CD3-PE), 
Green (IgMa Bio-StAv AL488). Top left control spleen from 2-12H/Vκ4 mouse. 
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Figure 5. Spontaneous cell death and BAFF responsiveness and receptor expression.  
A, Purified B cells were cultured for the indicated times at which time they were collected 
and cell death analyzed. B, Purified B cells were cultured in the absence or presence of 
increasing concentrations of BAFF for 72hs later at which time cell death was assessed by 
flow cytometry. C, Top pane,l representative histograms showing staining for the there 
different BAFF receptors. Bottom panel, Compiled data normalized to non-Tg control. * 
Significant difference ( p<0.05), ** (p<0.01) 
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CHAPTER 3 
An uncoupling of the BCR from its signalsome regulates 
high affinity anti-Sm marginal zone but not follicular B 
cells. 
 
ABSTRACT 
Multiple mechanisms of tolerance regulate self-reactive B cells.  Encounter with self-
antigen can lead B cells to a state of anergy, normally characterized by cell unresponsiveness 
to BCR stimulation or other activating stimuli.  In chapter 2, I described mice (2-12H/Vκ4) 
transgenic for B cell receptors (BCRs) specific for Sm, a ribonucleoprotein antigen targeted 
in systemic lupus erythematosus (SLE). In these mice, anti-Sm mature B cells are anergic 
and Ab secretion is severely impaired, more so than 2-12H B cells. Anti-Sm 2-12H Fo B 
cells are anergic, but MZ B cells are functional. I hypothesize that both 2-12H/Vκ4 Fo and 
MZ B cells are regulated and anergic. To test this hypothesis, I determined the ability of the 
BCR on cells of each subset to signal in response to BCR ligation.  I find that the BCRs of 2-
12H and 2-12H/Vκ4 anti-Sm Fo B cells signal following BCR ligation, as measured by 
general protein tyrosine phosphorylation and phosphorylation of the BCR signaling 
intermediates Syk and ERK.  However, while 2-12H MZ B cells signaled efficiently in 
response to BCR ligation, 2-12H/Vκ4 MZ B cells exhibit a weak protein tyrosine 
phosphorylation response and little increase in Syk and ERK phosphorylation. BCR ligation 
of 2-12H/Vκ4 Fo an MZ B cells induces rapid cell death, which can be explained by an 
imbalance in pro- and anti-apoptotic proteins that favors apoptosis.  2-12H/Vκ4 MZ B cells 
are also unable to respond to endogenous self antigens, since in contrast to 2-12H MZ B 
cells, they do not constitutively generate anti-Sm pre-plasma cells and are not activated by an 
increase in apoptotic cell load.  Thus, we conclude that 2-12H/Vκ4 MZ B cells are anergic 
due to a significant uncoupling of the BCR from its signalsome.   
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INTRODUCTION 
 Immune tolerance is paramount for the prevention of autoimmune diseases. B cells 
developing in the bone marrow are subject to several mechanisms of tolerance to prevent the 
differentiation of functional self-reactive B cells.  Many autoreactive B cells undergo 
differentiation and are regulated by anergy characterized by a state of non-responsiveness to 
BCR-mediated activation 1, 2, 3, 4, 5, 6.  In some cases, anergic B cells have low BCR levels, a 
short life span, are excluded from the follicles, and are unable to induce a normal BCR 
signaling cascade 7, 8, 9, 10.  Recently, anergic B cells have been shown to arrest at a 
transitional 3 stage (although thought to be incorrect and renamed An1) of differentiation and 
are not mature Fo B cells 11.  However, other anergic B cells have BCRs that are capable of 
signal transduction, have normal BCR levels, and normal life spans 11, 12, 13, 14. These 
contrasting characteristics could be explained by differences in the form of the self-antigen, 
as the level of self-antigen, when antigen is encountered during differentiation, or the affinity 
of the BCR.  
Why some anergic B cells are unable to tranduce a BCR signal is still unclear. One 
possibility is that chronic antigen engagement of the BCR results in a physical dissociation of 
the Igα and Igβ signaling components of the BCR from Ig, thereby preventing antigen from 
initiating signal transduction 15, 16, 17, 18.  However, this cannot be the only mechanism, as in 
the case of anergic anti-insulin and anti-ssDNA B cells, signal transduction (cell 
phosphorylation levels) occurs normally following BCR ligation 9, 12. Partial defects in signal 
transduction could result in B cell anergy and explain the differences between anergic B cells 
of different specificities. For example, anergic anti-insulin B cells are defective in Ca2+ 
mobilization and NF-AT expression and translocation to the nucleus 12. In addition, the 
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balance between pro and anti-apoptotic protein expression is an important factor regulating B 
cells survival 19, 20, 21, 22, 23, 24.  Anti-HEL B cells deficient in the pro-apoptotic protein Bim are 
able to respond to stimulation and are not anergic 25.  The expression of pro- and anti-
apoptotic proteins is regulated by multiple pathways such as NF-κB and Akt 26, 27, 28, 29.   
Previous analyses of B cell anergy have generally considered B cells as a single 
homogeneous population, since in most cases the self-reactive B cells belonged to a single 
subset. However, some autoreactive B cells are selected into multiple B cell subsets, and the 
B cells of each have different requirements for activation 30, 31.  This is clearly the case for B 
cells specific for the self-antigen Sm 32, 33, 34. Sm is a ribonucleoprotein that is frequently 
targeted by the immune system in systemic lupus erythematosus (SLE).  Its presence in 
human SLE is associated by renal disease and a poor prognosis 35, 36.  Analysis of anti-Sm B 
cells in 2-12H Tg mice indicates that anti-Sm B cells are present as transitional, follicular 
(Fo), marginal zone (MZ), B-1, and pre-plasma cells (pre-PCs), and that these cells are 
regulated differently.  Whereas, 2-12H Fo B cells are anergic, anti-Sm MZ and B-1 B cells 
are functional and can be activated by self-antigen 33, 37, 38.  In addition, some anti-Sm B cells 
are activated to become pre-PCs before undergoing apoptosis 32. Thus, for some autoreactive 
B cells regulation is determined by their subset identity.  
In the previous chapter, we demonstrated that anti-Sm B cells mice carrying the 2-
12H transgene and a Vκ4 L chain transgene are selected into mature Fo and MZ B cell 
subsets, but in contrast to 2-12H Tg mice, are not activated by toll-like receptor (TLR) 
agonists, and therefore are anergic. To understand the mechanism for anergy of anti-Sm B 
cells, and how these Fo and MZ B cells differ, I have investigated the ability of these cells to 
transduce a signal through their BCRs.  I find that Fo and MZ B cells differ in their ability to 
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signal transduce through their BCRs. Since the BCRs of Fo and MZ B cells are identical in 
these mice, these data indicate that B cell subset influences the mechanism of anergy.  
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MATERIALS AND METHODS 
 
Mice 
Anti-Sm 2-12H Tg mice and 2-12H/Vk4 double Tg mice have been described previously 
(Chapter 2) 34. Merkd mice were obtained from Dr. G. Matsushima (University of North 
Carolina at Chapel Hill) and bred with 2-12H Tg and Vκ4 Tg mice. 2-12H/Vk4 Merkd Tg 
mice were subsequently generated by crossing 2-12H Merkd+/- Tg and Vκ4 Merkd+/- Tg mice.  
 
Flow Cytometry 
Single-cell suspensions were prepared and analyzed as described in chapter 2. The Abs 
specific for IgM, B220, CD21, CD23 and CD138 were obtained from BD Biosciences.  
For intracellular staining of pro and anti-apoptotic proteins, after the indicated times, cells 
were fixed with 2% PFA (Electron Microscopy Sciences) and permeabilized with BD 
Perm/Wash™ buffer (BD Biosciences) containing saponin. Anti-Bim (poly Rab) and anti-
Bax (Ms IgG1 6A7) were obtained from BD Biosciences and Bcl-XL PE (SC-8392) was 
purchased from Santa Cruz Biotechnology. Anti-Rabbit Alexa647 and anti-Ms IgG1 
Alexa488 were obtained from Probes-Invitrogen.  
 
Cell purification 
Splenic B cells were isolated by negative selection using IMagTM Streptavidin Particles Plus 
(BD Biosciences) following manufacturers protocol for magnetic labeling and separation as 
described in Chapter 2. B cells were 92–98% pure as determined by flow cytometry.  
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In vitro stimulation 
Purified B cells were (1x106/ml) were cultured in 24 well plates in complete RPMI 
containing 10% FCS, L-glutamine, penicillin, streptomycin, and 2-mercaptoethanol. For 
proliferation analysis B cells were labeled with CFSE (Probes-Invitrogen) at a concentration 
of 1 µM for 10 min at room temperature. 
Cells were stimulated with 10 µg/ml of F(ab’)2 fragment goat anti-mouse IgM (Jackson 
Immunoresearch) or left unstimulated. For survival and proliferation analysis cells were 
stimulated for 72hs then washed and stained with LIVE/DEAD dead cell stain kit (Probes-
Invitrogen). To analyze pro and anti- apoptotic protein expression B cells were cultured for 
the indicated times. 
 
Cell signaling by Flow Cytometry 
Cell signaling was determined by flow as previously described Nolan  39, 40, 41. Briefly, B cells 
were purified and placed in RPMI with 2%FCS. Cells were left at 37°C for 30 min and the 
stimulated with 10 µg/ml of F(ab’)2 fragment goat anti-mouse IgM (Jackson 
Immunoresearch). At indicated times; cells were fixed with 2 % PFA for 15 min. Cells were 
then permeabilized for 30 min with ice cold MeOH. Cell were then washed with PBS 
containing 2%FCS and blocked with mAb 2.4G2 for 15 min. Cells were then stained with 
B220, CD21 and CD23 (BD Biosciences) and with either anti-phospho-ERK(p44/42) Ab 
(Cell Signaling Technology), anti-phospho-Syk or anti-phosphotyrosine (BD Biosciences) 
for 1 hr. Phosphorylation levels were determined by flow cytometry. 
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ELISAs 
Quantitation of anti-Sm Abs, total IgM and IgMa in mouse serum was done by ELISA as 
previously described in Chapter 2 
 
Statistical analysis 
The Student t test was used to assess the significance of the differences between groups. A 
value of p< 0.05 was considered significant. 
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RESULTS 
Anti-Sm B cells fail to proliferate and undergo cell death in response to BCR cross-linking.  
 High affinity anti-Sm 2-12H/Vκ4 B cells appear to be anergic.  They are unable to 
survive in the presence of non-Tg B cells, probably due to a defective responsive to the pro-
survival factor BAFF, and unable to secrete normal levels of antibody following LPS 
stimulation.  B cell anergy is also characterized by an inability to proliferate in response to 
BCR ligation and an inability of the BCR to transducer a signal following ligation 2.  To 
determine whether 2-12H/Vκ4 anti-Sm B cells are responsive to BCR crosslinking, we 
assessed the ability of anti-IgM to induce these B cells to proliferate. Enriched splenic B cells 
from non-Tg, 2-12H, and 2-12H/Vκ4 mice were CFSE labeled and cultured in vitro for 72hs 
in the presence of anti-IgM.  Cells were then harvested, and cell death and proliferation were 
determined by flow cytometry analysis. While non-Tg B cells underwent several cycles of 
proliferation, 2-12H and 2-12H/Vκ4 B cells underwent little if any proliferation (Fig. 1A). 
Moreover, most 2-12H and 2-12H/Vκ4 B cells underwent cell death upon anti-IgM 
stimulation (Fig. 1B).  Thus, 2-12H and 2-12H/Vκ4 B cells are unable to proliferate and 
undergo cell death in response to BCR cross-linking. 
 
Signaling transduction is normal in anti-Sm B cell following anti-IgM cross-linking 
 The lack of anti-Sm cell proliferation and consequential cell death following BCR 
crosslinking could be due to defective signal transduction that uncouples the BCR from 
downstream signaling pathways 11, 15, 16, 18. We assessed the phosphorylation of several key 
proteins to determine whether anti-Sm B cells could invoke normal signal transduction 
following BCR stimulation 42. We assessed general cell phosphorylation levels (p-Tyr), the 
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phosphorylation of an early member of the signaling pathway induced by BCR (p-Syk) and 
of a downstream member (p-Erk).  Fo, transitional, and MZ B cells differ in the robustness of 
protein phosphorylation following BCR cross-linking, and therefore spleen purified B cells 
that vary in the representation of the these three B cell subsets could lead to inaccurate 
interpretations of BCR signaling ability 31.  Therefore, we examined the ability of B cells 
from each subset to respond separately using flow cytometry, as described by Nolan et al.  39, 
40, 41. Enriched B cells were stimulated with anti-IgM at10 µg/ml, a dose used to determine 
signaling defects in other anergic B cells, and protein phosphorylation was assessed over 
time. To control for experimental variations, non-Tg B cell phosphorylation was used as a 
control for each time point.  Non-Tg B cells were mixed with either 2-12H or 2-12H/Vκ4 B 
cells at a 1:1 ratio and subjected to anti-IgM stimulation. 2-12H and 2-12H/Vκ4 B cells were 
distinguished from non-Tg B cells by IgMa staining.  In addition to staining with anti-
phosphoprotein antibodies, cells were stained with anti-CD21, CD23 and B220 to distinguish 
B cell subsets (Fig. 2A).  General Tyr and Syk phosphorylation was similar in magnitude and 
duration in Fo B cells from mice of all three mouse lines in response to anti-IgM (Fig. 2B top 
and middle left panel).  Erk phosphorylation was similar in non-Tg or 2-12H/Vκ4 B cells, 
but consistently greater in 2-12H Fo B cells (Fig. 2B, bottom left).  In striking contrast, 2-
12H/Vκ4 MZ B cells consistently exhibited diminished general p-Tyr, p-Syk, and p-ERK 
levels after anti-IgM stimulation (Fig. 2B, right panels).  2-12H and non-Tg MZ B cells 
showed a similarly strong phosphorylation following anti-IgM stimulation.  These data 
suggest that the BCR on 2-12H/Vκ4 MZ B cells is largely uncoupled from the BCR 
signalsome.  This is not the case for 2-12H/Vκ4 Fo B cells indicating that BCR signal 
impairment in these cells likely involves a discrete branch of the BCR signaling cascade.  
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Thus, impaired BCR signaling by 2-12H/Vκ4 Fo and MZ B cells occurs through different 
mechanisms, despite the expression of identical anti-Sm BCRs.  
 We also assessed phosphorylation prior to stimulation to determine whether there was 
any increase in the basal levels, as noted with other autoreactive B cells 43.  p-Tyr and p-Syk 
levels were significantly higher in 2-12H and 2-12H/Vκ4 Fo B cells compared to non-Tg Fo 
B cells (Fig. 2C). However, p-ERK levels were similar in Fo B cells from mice of all three 
strains (Fig. 2C).  In contrast, basal phosphorylation levels in 2-12H/Vκ4 MZ B cells were 
not significantly different from non-Tg MZ B cells.  These data suggest that the BCRs of 2-
12H and 2-12H/Vκ4 Fo B cells may constitutively engage antigen resulting in a high basal 
phosphorylation level of Syk and other proteins.  However, this constitutive signal does 
result in high Erk phosphorylation.  In addition, these data indicate that the 2-12H/Vκ4 MZ B 
cells are not constitutively signaling, consistent with the uncoupling of the BCR from its 
signalsome indicated above.  
 
Anti-Sm B cells up-regulate pro-apoptotic proteins following BCR activation 
 Bim and Bax, two pro-apoptotic proteins, have been shown to regulate B cell induced 
cell death, while Bcl-XL plays a positive role in B cell survival 19, 23, 24. Thus, a shift in the 
balance of pro- and anti-apoptotic proteins to favor apoptosis in anti-Sm B cells following 
BCR stimulation could explain the cell death induced by anti-IgM stimulation.  To examine 
this possibility purified B cells were stimulated with anti-IgM (10 µg/ml) for 16 and 40 hrs, 
and protein expression measured by intracellular flow cytometry. Expression levels of Bim 
and Bax were similar in the absence of stimulation in B cells from all three strains, while 
Bcl-XL levels in 2-12H and 2-12H/Vκ4 B cells were somewhat lower than in non-Tg B cells 
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(Fig. 3).  At 16 hs post-stimulation, Bim and Bax levels had increased in 2-12H and 2-
12H/Vκ4 B cells and increased further by 40 hrs post-stimulation.  However, Bim and Bax 
levels did not change in non-Tg B cells.  In contrast, there was no change in Bcl-XL levels in 
2-12H and 2-12H/Vκ4 B cells at 16 hrs and only a modest increase by 40 hrs that resulted in 
levels similar to those in non-Tg B cells (Fig. 3). Thus, BCR crosslinking of anti-Sm B cells 
from both 2-12H and 2-12H/Vκ4 mice induces a shift in the balance of pro- and anti-
apoptotic protein expression in favor of apoptosis, consistent with their inability of these cells 
to survive after BCR cross-linking (Fig. 1).  
 
2-12H/Vκ4 B cells were defective in response to endogenous autoantigen in vivo  
 We recently described a population of pre-PCs that are characterized by intermediate 
levels of the CD138 (CD138int) 32.  They appear to differentiate in response to antigen 
stimulation, since they are not generated in the absence of antigen and are reduced in number 
in mice with defective BCR signal transduction.  Anti-Sm pre-PCs are regulated to prevent 
differentiation to the antibody secreting cell (ASC) stage in non-autoimmune mice, but not in 
autoimmune mice.  To determine whether the anti-Sm B cells of 2-12H/Vκ4 mice can 
differentiate to the CD138int pre-PC stage in response to endogenous autoantigen, we 
determined the frequency of anti-Sm pre-PCs in these mice by flow cytometry.  We observed 
a ~4-fold reduction in the frequency of CD138int pre-PCs in the spleens of 2-12H/Vκ4 mice 
compared to 2-12H and non-Tg mice (Fig. 4).  Thus, activation of 2-12H/Vκ4 B cells by 
endogenous autoantigen is impaired, consistent with the defects in BCR signaling identified 
by anti-IgM stimulation.   
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The inability to respond to endogenous autoantigen was further tested by introducing 
a defect in apoptotic cell clearance into 2-12H/Vκ4 mice.  Apoptotic cells expose Sm antigen 
on their surface and induce an anti-Sm response in non-Tg and 2-12H mice.  Moreover, mice 
with a defect in the Mer gene (Merkd) have a macrophage defect in the phagocytosis of 
apoptotic cells, which results in a mild lupus-like disease  44, 45, 46and the constitutive 
production of anti-Sm antibodies in 2-12H mice  33.  To determine whether higher levels of 
apoptotic cell antigens resulting from a defect in Merkd could induce activation of 2-12H/Vκ4 
B cells, we generated 2-12H/Vκ4/Merkd mice.  As shown in Fig. 5, 2-12H/Vκ4 mice with 
and without the Merkd mutation had similar frequencies of Fo, MZ and Tr B cells, indicating 
that Merkd had not grossly affected differentiation to the Fo and MZ B cell subsets.  Serum 
was collected from mice at 6 months of age and IgM and anti-Sm levels determined by 
ELISA.  As shown in Fig. 5B, 2-12H/Vκ4 and 2-12H/Vκ4 Merkd mice did not differ in IgM 
or anti-Sm antibody levels.  Thus, unlike 2-12H anti-Sm B cells, the anti-Sm B cells of 2-
12H/Vκ4 mice were not activated by defective clearance of apoptotic cells.   
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DISCUSSION 
In this study we have established that anti-Sm B cells are regulated in part through a 
defect in BCR signaling. Anti-Sm B cells mature to the Fo and MZ B cell stages in both 2-
12H and 2-12H/Vκ4 mice and they have comparatively normal half-lives.  However, we 
show here that 2-12H/Vκ4 Fo and MZ B cells undergo cell death in response to anti-BCR 
stimulation rather than proliferate, as occurs with non-Tg B cells.  The failure to respond to 
anti-BCR stimulation reflects an in vivo defect in activation.  2-12H/Vκ4 mice have few anti-
Sm pre-plasma cells, which are antigen dependent, and the Merkd defect does not induce a 
chronic anti-Sm response. In contrast, 2-12H mice have a large anti-Sm pre-plasma cell 
population and the Merkd mutation induces a chronic anti-Sm response 32, 33.  This defect in 
BCR-mediated activation is in addition to the inability to secrete normal levels of Abs to LPS 
and CpG by anti-Sm B cells of both strains (Chapter 2), and thus, anergy in anti-Sm B cells 
affects both TLR and BCR activation.  These characteristic are similar to those displayed by 
other anergic systems, such as the anti-HEL and anti-dsDNA, although B cells of both 
specificities also show defects in B cell development and activation. In contrast, anti-ssDNA 
B cells, which do not undergo developmental arrest, are able to proliferate following anti-
BCR stimulation 9.  Anti-insulin B cells show the greatest similarity to 2-12H/Vκ4 anti-Sm B 
cells.  They differentiate to Fo and MZ B cells, but are unable to undergo BCR induced 
proliferation 12, 13.  Thus, there are multiple forms of anergy, and which is exhibited by a 
given B cell is dependent on the form of the antigen and affinity of the BCR for the antigen.  
The failure of anti-Sm Fo B cells to undergo proliferation following anti-IgM 
stimulation is not due to a general uncoupling of the BCR from its induced intracellular 
signal, as has been suggested for B cells of other self-specificities 18.  This is evident from 
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general p-tyrosine induction following anti-IgM treatment, and most importantly, by levels of 
phosphorylated Syk and Erk, an early and intermediate event in the signaling cascade, 
respectively, that equals or exceeds the levels in non-Tg B cells.  Thus, 2-12H/Vκ4 Fo B 
cells are able to initiate the BCR signaling cascade indicating that, rather than a general 
uncoupling of the BCR from the signalsome, anergy is mediated by disruption of one or more 
signaling pathways from the BCR. An example of this is seen in anti-insulin B cells where 
BCR induced phosphotyrosine is normal, but there is a defect in IP3 metabolism and a 
reduced basal NFATc1 expression and activation.  
Pathways leading to proliferation and survival are likely disrupted in anti-Sm Fo B 
cells of 2-12H and 2-12H/Vκ4 mice, although the failure to proliferate could be secondary to 
the inability to deliver a survival signal.  In support of this latter view, the few surviving 2-
12H and 2-12H/Vκ4 B cells after IgM stimulation have undergone one or more divisions, as 
well as have some cells prior to apoptosis, (Fig. 1A) suggesting that the anti-Sm BCR is able 
to signal B cell proliferation.  Cell death appears to be mediated by the pro-apoptotic proteins 
Bim and Bax, since anti-IgM stimulation induces an increase in these molecules in anti-Sm B 
cells, but not non-Tg B cells.  Bim expression in particular has a significant role in BCR 
induced cell death, since Bim-deficient B cells are refractory to activation induced cell death 
following anti-IgM stimulation 47, 48, and anergic anti-HEL B cells that lack Bim undergo 
maturation to the Fo B cell stage and break tolerance 25.  In addition to alteration of pro-
apoptotic protein production, anergic anti-Sm B cells also exhibited altered production of the 
anti-apoptotic protein Bcl-XL that might have counterbalanced the effects of Bim and Bax.  
Bcl-XL binds pro-apoptotic proteins inhibiting their function.  The anti-Sm BCR may be 
unable to activate phosphoinositol-3-kinase (PI3K) leading to activation of the Akt survival 
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pathway and a failure to inhibit the upregulation of pro-apoptotic gene expression 28, 29. 
Furthermore, the effect of defective PI3K activation can be observed in CD19KO B cells 
which are defective in proliferation and survival following BCR stimulation probably due to 
defective Akt and Ca2+ activation 49, 50. Alternatively, a failure of NFκB activation could lead 
to a lack of Bcl-XL upregulation, leaving the cells unable to be rescued from BCR induced 
death 27. Whatever the upstream defect may be, it is clear from these data that anti-Sm Fo B 
cells are intrinsically wired to undergo cell death following BCR engagement.  
The biochemical mechanism of regulation of anti-Sm MZ B cells from 2-12H/Vκ4 
mice is different from that for Fo B cells from these mice.  2-12Vκ4 MZ B cells show 
reduced overall protein phosphorylation, as well as reduced levels of phosphorylated Syk and 
Erk compared to non-Tg and 2-12H MZ B cells (Fig. 2).  These data suggest that the BCR on 
anti-Sm MZ B cells of 2-12H/Vκ4 mice is uncoupled from the signalsome.  Thus, anti-Sm 
MZ and Fo B cells are regulated at different levels in the BCR signaling cascade.  This 
difference may be inherent in the cell type (Fo vs. MZ) rather than a function of affinity, 
since the 2-12H/Vκ4 Fo and MZ B cells have identical BCRs.  However, we cannot rule out 
that MZ B cells by virtue of their location have greater access to antigen than Fo B cells 
leading to regulation at different levels in the signaling pathway.   
Interestingly, 2-12H anti-Sm MZ B cells are not uncoupled from the signalsome, 
since they show similar protein phosphorylation to non-Tg MZ B cells, including Syk and 
Erk, suggesting that they are functional.  Indeed, apoptotic cells, which expose Sm on the 
outer leaflet of their plasma membranes, induce an anti-Sm response in 2-12H mice 33, and 
concomitantly induce a loss of anti-Sm MZ B cells (Kara Conway, and S.H.C., unpublished 
observation).  In addition, 2-12H MZ B cells are significant precursors to the large anti-Sm 
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pre-plasma cell pool (Kara Conway and S.H.C., unpublished observation) that is present in 
non-autoimmune mice suggesting that they are continually activated 32.  The evidence 
indicating that 2-12H MZ B cells have not uncoupled their BCR from the signalsome is 
consistent with evidence suggesting that 2-12H MZ B cells are functional. The difference 
between 2-12H and 2-12H/Vκ4 MZ B cells is solely with the L chain. L chain use by 2-
12H/Vκ4 MZ B cells is fixed in contrast to diverse L chain use by 2-12H MZ B cells.  Single 
cell sequencing identified over 20 different L chains expressed by anti-Sm MZ B cells 
(Suzanne McCray and S.H.C., unpublished observation). Thus, affinity for Sm is likely the 
determining factor for the difference in regulation between the MZ B cells of these two 
mouse strains.   
 ERK signaling is proposed to be a molecular switch to prevent ASC differentiation by 
anergic B cells upon TLR stimulation 51. The basal phosphorylation level of ERK in anergic 
anti-HEL B cells is elevated compared to naïve anti-HEL B cells preventing differentiation to 
ASCs by CpG or LPS stimulation and inhibition of ERK phosphorylation restores 
responsiveness to CpG and LPS 51, 52. The block in LPS and CpG activation by 2-12H/Vκ4 B 
cells (Chapters 2 and 4) is unlikely to be mediated by this mechanism, since 2-12H/Vκ4 Fo B 
cells do not exhibit elevated basal ERK phosphorylation levels. Basal phosphorylated Syk 
levels and general protein phosphorylation levels are elevated in 2-12H/Vκ4 Fo B cells 
confirming chronic stimulation through the BCR.  MZ B cells do not show elevated general 
protein phosphorylation or Syk and ERK phosphorylation consistent with the evidence that 
their BCRs are uncoupled from the signalsome. The conclusion that high basal ERK 
phosphorylation is not involved is reinforced by the observation that inhibition of ERK 
phosphorylation does not restore responsiveness to LPS or CpG (Chapter 4).  Thus, the ERK 
94
molecular switch mechanism for blocking TLR-mediated activation may not be a 
generalizable phenomenon and may be dependent on any number of variables, such as the 
affinity/avidity of the BCR, antigen concentration, and coincident signals through other 
receptors.   
 In summary, antigen activation of anti-Sm B cells from 2-12H/Vκ4 mice is defective 
both in vitro and in vivo, but that biochemical mechanism is different for anti-Sm Fo and MZ 
B cells.  The BCRs on anti-Sm Fo B cells are signaling competent, but are defective in 
delivering a cell survival signal to block antigen activated cell death caused by the 
upregulation the pro-apoptotic proteins Bim and Bax.  In contrast, the BCR of anti-Sm MZ B 
cells from these mice is uncoupled from its signalosme preventing the delivery of a signal, 
even Syk phosphorylation, a membrane proximal signaling event.  This uncoupling is not 
evident in anti-Sm MZ B cells of 2-12H mice implying a role for affinity in uncoupling.  
Neither Fo, nor MZ B cells, from these mice show high basal ERK phosphorylation arguing 
against the involvement of the ERK signaling molecular switch in preventing TLR-mediated 
activation.  Thus, we propose the existence of an alternative biochemical pathway for 
blocking TLR activation of autoreactive B cells that may be more physiologically relevant to 
anti-self B cells specific for antigens targeted in systemic lupus erythematosus and other 
autoimmune diseases.  
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Figure 1.  Responses of 2-12H and 2-12H/Vκ4 B cells to in vitro anti-IgM stimulation.  
A, Representative data of proliferative responses of CFSE-labeled B cells from wild-type and 
anti-Sm Tg mice incubated for 72 hr in the presence of 10 µg/ml F(ab’)2 anti-mouse IgM. 
Cell divisions as assessed by CFSE dye dilution.  B, Cell survival as determined by flow 
cytometric analysis on isolated splenic B cells cultured in the presence of 10 µg/ml F(ab’)2 
anti-mouse IgM for 72 hr. Cells negative for live/dead staining (y axis A)  were scored as 
viable. Numbers show percentage of viable cells. Results represent the mean of three mice.  
Significant difference ** (p<0.01) and *** (p<0.001). 
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Figure 2. Subset-specific BCR-mediated signaling analysis of anti-Sm B cells by flow 
cytometry. 
A, Purified B cells from each strain were stimulated as in Fig 1 for 5, 10, 15 and 20 minutes 
or unstimulated, fixed with formaldehyde, and permeabilized with methanol. Cells were then 
stained with the anti phospho-protein of interest plus IgM, CD21 and CD23 to distinguish 
subsets and analyzed by flow cytometry. Top panel shows example of gating scheme used to 
determine protein phosphorylaton in Fo and MZ B cells following stimulation (5min). 
Bottom, p-tyr (top), p-Syk (middle), p-ERK (bottom) phosphorylation kinetics was assessed. 
Fold increase over M.F.I. of unstimulated cells (0 min) was plotted. Data is representative of 
two independent experiments with two mice of each strain used per experiment.  B, Basal 
phosphorylation levels of specific phospho-protein in unstimulated B cells. Data represents 
fold increase in MFI over unstimulated non-Tg B cells. Significant difference * (p<0.05) and 
** (p<0.01). 
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Figure 3. Flow cytometric anslysis of Bim, Bax and Bcl-XL expression following anti-IgM 
stimulation. 
A, Representative histogram showing changes in protein expression patterns in B cells from 
the indicated strains after 40hs of anti-IgM stimulation. B, Compiled data of protein 
expression of untreated (PBS) or anti-IgM (10 µg/ml F(ab’)2) treated B cells for the indicated 
times.  
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Figure 4. Analysis of CD138-expressing pre-PC B cells. 
Top, representative histograms used to determine the presence of pre-PCs. Percentages are 
indicated. Bottom, Frequency of  pre-PCs cells among total B cells (n ≥ 5). Significant 
difference * (p<0.05) and *** (p<0.001). 
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Figure 5. Analysis of 2-12H/Vκ4/Merkd mice.  
A, Comparison of total, Fo, MZ and Tr B cell numbers in 2-12H/Vκ4 (n=11) and 2-
12H/Vκ4/Merkd (n=8) mice. B, Serum total IgMa and anti-Sm IgMa levels were measured by 
ELISA. 
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CHAPTER 4 
TLR induced antibody secretion by anergic anti-Sm B 
cells is regulated by cell death and inhibition to undergo 
plasma cell differentiation 
 
ABSTRACT 
Anergic B cells are unable to differentiate to antibody-secreting plasma cells (PCs) 
upon stimulation with toll-like receptor (TLR) agonists. How PC differentiation is blocked is 
not fully understood. In this report, I describe the regulation of PC differentiation by anergic 
anti-Sm B cells from mice transgenic for the 2-12H gene (2-12H) and the 2-12H gene and a 
Vκ4 gene (2-12H/Vκ4). Both mice generate anti-Sm B cells, but while 2-12H mice generate 
anergic anti-Sm follicular (Fo) B cells, but functional anti-Sm marginal zone (MZ) B cells, 2-
12H/Vκ4 mice generate anergic anti-Sm Fo and MZ B cells. I hypothesize that anti-Sm B 
cells are block prior to PC differentiation following TLR stimulation. Anergic 2-12H and 2-
12H/Vκ4 anti-Sm B cells proliferate in response to TLR stimulation.  However, both 2-
12H/Vκ4, and to a lesser degree, 2-12H B cells, are defective in antibody secretion. Two 
mechanisms regulate antibody secretion: activation-induced cell death and a block in PC 
differentiation, although the contributions of these mechanisms differ depending on B cell 
subset identity. These findings also indicate that, although activation induced cell death is 
functional at the transitional B cell stage, the block in PC differentiation does not become 
fully functional until the Fo B cell stage.  The regulation of PC differentiation of anergic anti-
Sm B cells is independent of ERK activation contrasting with the block in PC differentiation 
by anergic anti-hen egg lysozyme (HEL) B cells, indicating the existence of an ERK 
independent mechanism for regulating PC differentiation by anergic B cells.   
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INTRODUCTION 
 The regulation of B cell differentiation to plasma cells (PCs) is critical to preventing 
the production of autoantibodies. Toll-like receptor (TLR) ligands are potent inducers of B 
cell activation, inducing proliferation and antibody secretion. Activation of B cells by TLR 
stimulation can bypass the requirements for other stimuli, such as cytokines or T cell help, in 
PC differentiation. As such, TLR activation has the potential danger of breaking tolerance 
and inducing autoimmune diseases. Autoreactive B cells can be regulated by multiple 
mechanisms 1, 2, 3, 4, 5, 6, 7. Anergy, a state characterized by cell unresponsiveness, can offer a 
potential window for break in tolerance due to the retention of self-reactive cells in the 
periphery.  Nonetheless, most anergic B cells remain unable to differentiate to PCs following 
TLR stimulation 8, 9, 10, 11. The mechanisms involved in the regulation of TLR activation of 
anergic B cells remains unclear, but it is important to understand how tolerance is maintained 
and broken for the design of new therapies for autoantibody-mediated diseases such as 
systemic lupus erythematosus. 
 PC differentiation is regulated by multiple transcription factors. B lymphocyte-
induced maturation protein-1 (Blimp-1) is considered the master regulator of PC 
differentiation 12, 13. Blimp-1 directly represses c-Myc, a protein involved in B cell 
proliferation, and therefore induces cell cycle arrest required for terminal PC differentiation. 
Pax-5, which functions to maintain B cell identity, is another target of Blimp-1 mediate 
suppression. Pax-5 represses, amongst many genes, the transcription factor gene XBP-1 and 
IRF-4 that are required for PC differentiation 14, 15, 16, 17, 18.    
 Anergic anti-HEL B cells are unable to differentiate to PCs following TLR 
stimulation (CpG or LPS). Chronic Ag engagement by the anti-HEL BCR leads to higher 
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basal levels of activated ERK, resulting in suppression of Blimp-1 expression 19, 20. Strong 
BCR signaling has been previously shown to also inhibit TLR induced PC differentiation of 
naïve B cells by an ERK-dependent mechanism 19, 21, 22. Thus, ERK acts as a molecular 
switch that governs expression of Blimp-1 expression and subsequent PC differentiation. 
 Anti-Sm B cells are regulated by multiple mechanisms of tolerance, including anergy.  
In anti-Sm 2-12H Tg mice, anti-Sm B cells are also regulated at a pre-PC stage. These cells 
express CD138 (a pan PC marker), but have not upregulated the expression of Blimp-1. 
Thus, anti-Sm B cells are activated to become PCs, but are blocked at an early PC stage from 
completing PC differentiation in non-autoimmune mice 23, 24, 25. High affinity anti-Sm from 
mice carrying both the 2-12H transgene and a Vκ4 transgene (2-12H/Vκ4 mice) have a more 
pronounced defect in antibody secretion following TLR stimulation than 2-12H mice 
(Chapter 2).  In addition, pre-PCs are almost absent in 2-12H/Vκ4 mice, indicating a 
regulation of PC differentiation prior to pre-PC stage (Chapter 3). This would suggest a role 
for BCR affinity in the establishment of regulatory mechanisms maintaining tolerance. 
Unlike the low affinity anti-Sm B cells from 2-12H/Vκ8 mice, 2-12H/Vκ4 B cells are 
positively selected into the MZ B cell subset. The presence of this mature subpopulation in 
addition to the Fo B cell population allows us to assess the impact of tolerance on MZ B cells 
and gain insight into the regulation of anti-Sm B cells. 
 Herein, I show that, although anti-Sm B cells are able to proliferate to TLR 
stimulation, they have a defect in antibody secretion and are regulated by a combination of 
activation-induced cell death and a block in PC differentiation. This block occurs prior to 
CD138, XBP-1 and IRF-4 upregulation.  Anti-Sm B cell death might be a consequence of 
increased Bim expression following TLR stimulation or a lag in the upregulation of Bcl-XL.  
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The degree at which each of the two mechanisms act is dependent on the B cell subset. 
Moreover, the influential role of the BCR affinity was readily apparent as 2-12H/Vκ4 B cells 
exhibit the highest degree of regulation affecting even MZ B cells.  The inhibition of ERK 
pathway did not restore anti-Sm antibody secretion as observed in anergic anti-HEL B cells. 
Thus, the mechanisms regulating TLR activation of anti-Sm B cell are influenced by BCR 
affinity and are independent of ERK activation, suggesting the existence of an ERK-
independent pathway in the regulation of PC differentiation by anergic B cells. 
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MATERIALS AND METHODS 
 
Mice 
Anti-Sm 2-12H Tg mice and 2-12H/Vκ4 double Tg mice have been described previously 
(Chapter 2).  
 
Flow Cytometry 
Single-cell suspensions were prepared and analyzed as described in chapter 2. The Abs 
specific for IgM, B220, CD21, CD23 and CD138 were obtained from BD Biosciences.  
For intracellular staining of pro and anti-apoptotic proteins, after the indicated times, cells 
were fixed with 2% PFA (Electron Microscopy Sciences) and permeabilized with BD 
Perm/Wash™ buffer (BD Biosciences) containing saponin. Anti-Bim (poly Rab) and anti-
Bax (Ms IgG1 6A7) were obtained from BD Biosciences and Bcl-XL PE (SC-8392) was 
purchased from Santa Cruz Biotechnology. Anti-Rabbit Alexa647 and anti-Ms IgG1 
Alexa488 were obtained from Probes-Invitrogen. For intracellular staining of transcription 
factors involved in PC differentiation cells were fixed with 2% PFA and permeabilized with 
ice cold MeOH for 30 min. Cells were stained with B220, IgM and CD138 (BD 
Biosciences). Cells were also stained with mouse anti-Pax-5 (Ms IgG1 BD Biosciences), 
rabbit anti-XBP-1 and goat anti-IRF-4 (Santa Cruz Biotechnology). Goat anti-Rabbit 
Alexa647 and goat anti-Mouse IgG1Alexa488 (Probes-Invitrogen) and donkey anti-goat Cy5 
(Jackson ImmunoResearch) were used as secondary Abs.  
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Cell purification 
Splenic B cells were isolated by negative selection using IMagTM Streptavidin Particles Plus 
(BD Biosciences) following manufacturers protocol for magnetic labeling and separation as 
described in Chapter 2. B cells were 92–98% pure as determined by flow cytometry.  
 
Cell sorting 
For cell sorting experiments, splenic cells were stained with anti-CD21, anti-CD23, anti-
B220 and anti-CD138 Abs (BD Biosciences) and propidium iodide added (to discriminate 
dead cells) and sorted on a MoFlo high-speed sorter (DakoCytomation). Sorted populations 
were >95% pure as determined by reanalysis. 
 
In vitro stimulation 
Purified or sorted B cells were (1x106/ml) were cultured in 24 well plates in complete RPMI 
containing 10% FCS, L-glutamine, penicillin, streptomycin, and 2-mercaptoethanol. For 
proliferation analysis B cells were labeled with CFSE (Probes-Invitrogen) at a concentration 
of 1 µM for 10 min at room temperature. 
Cells were stimulated with (0.1, 1 or 10 µg/ml) LPS or (0.1 or 1 µg/ml) CpG (InvivoGen) as 
indicated. For survival and proliferation analysis cells were stimulated for 72hs then washed 
and stained with LIVE/DEAD dead cell stain kit (Probes-Invitrogen). To analyze pro and 
anti- apoptotic protein expression B cells were cultured for the indicated times. 
For analysis of XBP-1, IRF-4 and Pax-5, sorted B cells were stimulated for 72 hs and 
analyzed by flow cytometry as described above. 
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Cell signaling by Flow Cytometry 
Cell signaling was determined by flow as previously described in Chapter 3. Cells were 
incubated for 30 minutes in the presence or absence of 10µM U0126 (Promega) to test the 
efficiency of the MEK inhibitor on ERK phosphorylation. Cells were stimulated with anti-
CD40 (BD Biosciences) for 15 min to induce maximum phosphorylation.  
 
ELISAs 
Quantitation of total IgM in supernatants was done by ELISA as previously described in 
Chapter 2. Supernatants were collected 72hs following stimulation. 
 
Statistical analysis 
The Student t test was used to assess the significance of the differences between groups. A 
value of p< 0.05 was considered significant. 
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RESULTS 
Anti-Sm B cells proliferate following TLR stimulation, but show enhanced cell death. 
We previously showed that 2-12H and 2-12H/Vκ4 B cells secrete significantly less 
antibody than non-Tg B cells following LPS or CpG stimulation. Since proliferation and 
antibody secretion are independently regulated, we determined whether anti-Sm B cells were 
similarly deficient in ability to proliferate following LPS and CpG stimulation.  Purified non-
Tg, 2-12H and 2-12H/Vκ4 B cells were CFSE labeled and simulated with different 
concentrations of LPS or CpG. Proliferation and cell death were assessed by flow cytometry 
gating on live cells (Fig. 1A-B). 2-12H B cells proliferate similarly to non-Tg B cells, and 
underwent multiple cycles of division at all ligand concentrations tested (Fig 2A, top two 
rows). Thus, 2-12H and 2-12H/Vκ4 B cells are responsive to LPS and CpG-induced 
proliferation signals indicating that their deficiency in antibody secretion is due to a selective 
deficiency in TLR-induced differentiation signals.   
 Proliferation of 2-12H and 2-12H/Vκ4 B cells differed from non-Tg B cells in two 
ways. First, 2-12H and 2-12H/Vκ4 B cells consistently underwent fewer cycles of cell 
division than non-Tg B cells. Second, a higher proportion 2-12H/Vκ4 B cells proliferated in 
response to both ligands than non-Tg or 2-12H Tg B cells (Fig. 2A, bottom row). One 
possible explanation for this is that dividing and non-dividing anti-Sm B cells were more 
likely to undergo cell death than non-Tg B cells. To test this possibility we determined the 
frequency of divided and non-divided B cells that had undergone cell death after LPS or CpG 
stimulation. Compared to non-Tg B cells, a higher percentage of dividing 2-12H and 2-
12H/Vκ4 B cells underwent cell death, which was most evident for the latter (Fig. 1C). Cells 
were lost at each cell cycle since a broad range of CFSE was detected, similar to the range 
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observed for live cells (data not shown). Thus, cell death is greater in 2-12H and 2-12H/Vκ4 
B cells than non-Tg B cells accounting for the overall fewer divisions per cell in these 
cultures (Fig. 1A). In addition, non-dividing 2-12H/Vκ4 B cells underwent a higher 
frequency of cell death than 2-12H and non-Tg B cells, which can account for the presence 
of fewer undivided 2-12H/Vκ4 B cells in these cultures (data not shown).  Undivided 2-12H 
and non-Tg B cells were not different in frequency of cell death, consistent the equal 
frequencies of undivided B cells in cultures of these cells.   
 Taken together, these results show that the anti-Sm B cells of 2-12H and 2-12H/Vκ4 
mice proliferate in response to TLR stimulation indicating that these B cells are responsive to 
LPS and CpG. However, both TLR ligands are less effective at rescuing anti-Sm B cells from 
cell death than non-Tg B cells.  
 
Anti-Sm B cells up-regulate Bim following LPS stimulation. 
 A balance between pro- and anti-apoptotic protein expression regulates activation 
induced B cell death 26, 27. We therefore determined if a shift in this balance to favor pro-
apoptotic protein expression could explain the deficiency in LPS or CpG-induced rescue of 
anti-Sm B cells. Splenic B cells were stimulated with LPS (10 µg/mL) and Bim, Bax and 
Bcl-XL protein expression profiles determined at 16 and 40 hrs post-stimulation by 
intracellular flow cytometry. At 16 hrs, Bim levels were equal in 2-12H/Vκ4 and non-Tg B 
cells, but slightly lower in 2-12H B cells. In addition, Bax levels were somewhat higher in 
non-stimulated 2-12H and 2-12H/Vκ4 B cells compared to non-Tg B cells. Bim and Bax 
expression increased in LPS stimulated B cells from mice of all three strains, although the 
Bim increase was greatest in 2-12H and 2-12H/Vκ4 B cells (Fig. 3). Bim and Bax had 
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increased further in 2-12H B cells and especially 2-12H/Vκ4 B cells at 40 hrs, while Bim had 
decreased to non-stimulated levels in non-Tg B cells (Fig. 3).   
In contrast, the levels of the anti-apoptotic protein Bcl-XL at 16hrs was lower in non-
stimulated 2-12H and 2-12H/Vκ4 B cells compared to non-Tg B cells. Bcl-XL expression 
levels, following LPS stimulaton, had increased substantially in non-Tg B cells at 16hrs, but 
little increased was observed in 2-12H and 2-12H/Vκ4 B cells. Bcl-XL levels were further 
increased in non-Tg B cells at 40 hrs, while 2-12H and 2-12H/Vκ4 B cells had up-regulated 
Bcl-XL expression to levels similar to the level in non-Tg B cells following LPS stimulation 
(Fig. 3). However, at this time Bim levels were much higher in these cells compared to non-
Tg B cells. Thus, LPS stimulation induces a shift in the balance in of pro- and anti-apoptotic 
proteins to favor survival in non-Tg mice, but to favor apoptosis in 2-12H and 2-12H/Vκ4 B 
cells, which may provide at least a partial explanation for the deficiency in survival of anti-
Sm B cells after LPS stimulation.   
 
Fo, MZ and transitional anti-Sm B cells are defective in Ab secretion following TLR 
stimulation. 
 We have previously shown that 2-12H and 2-12H/Vκ4 Fo and MZ B cells are 
defective in BCR-mediated activation through different biochemical mechanisms. To 
determine whether Fo and MZ B cells are equally defective in TLR-mediated antibody 
secretion, we sorted transitional, Fo, and MZ cells for in vitro LPS or CpG stimulation.  
Splenic B cells were stained for B220, CD21, CD23, and CD138 expression and transitional 
(B220+, CD21-, CD23-), Fo (B220+, CD21+, CD23+), and MZ (B220+, CD21high, CD23low) 
were sorted (Fig. 4A). Pre-PCs were excluded by CD138 expression. Sorted cells were 
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cultured and stimulated with TLR ligands and supernatants collected for measurement of 
secreted antibody levels by ELISA after 4 days. As shown in Figs. 4B-D, 2-12H and 2-
12H/Vκ4 B cells of all three subsets secreted less antibody in response to LPS and CpG than 
B cells of the corresponding population from non-Tg mice, with 2-12H/Vκ4 B cells 
consistently showing the lowest levels. R-848 (a TLR7 agonist) and poly I:C (a TLR3 
agonist) stimulation generated a similar pattern of antibody secretion by Fo B cells (data not 
shown). Thus, we conclude that B cells of all three subsets from 2-12H and 2-12H/Vκ4 mice 
are profoundly deficient in antibody secretion following TLR activation, consistent with their 
deficient responses to BCR activation (Chapter 3). This inability to secrete antibody extended 
to transitional B cells 2-12H/Vκ4 B cells indicating that the defect in TLR induced antibody 
secretion occurs at or before the transitional B cell stage (Fig 4D). 
 
Regulation of anti-Sm B cell secretion is independent of ERK phosphorylation. 
 ERK activation plays a central role in blocking TLR activation of anergic anti-HEL B 
cells by serving as a molecular switch that integrates signals from multiple receptors thereby 
controlling ASC differentiation. ERK is constitutively phosphorylated in anti-HEL B cells 
due to chronic BCR stimulation and although the mechanism for blocking ASC 
differentiation has not been elucidated, inhibition of ERK phosphorylation in these cells 
restores normal secretion by LPS and CpG activation 19, 20. We have previously shown that 
basal phospho-ERK levels are not elevated in Fo and MZ B cells of 2-12H and 2-12H/Vκ4 
mice (Chapter 3) suggesting that ERK signaling does not regulate TLR activation of these 
cells. To test this possibility further, we stimulated non-Tg and 2-12H/Vκ4 B cells with LPS 
or CpG in the presence or absence of the MEK inhibitor U0126 that blocks ERK 
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phosphorylation 28. 2-12H/Vκ4 B cells displayed diminished antibody secretion following 
either LPS or CpG stimulation compared to non-Tg B cells, and antibody secretion was not 
restored by the addition of U0126 (Fig 3A and 4B). U0126 inhibited ERK phosphorylation, 
since U0126 abrogated anti-CD40-induced ERK phosphorylation in these cells (Fig 4C). 
These results demonstrate that the inhibition of TLR-induced ASC differentiation by 2-
12H/Vκ4 B cells is independent ERK activation, suggesting the existence of an alternative 
regulatory mechanism for blocking ASC differentiation of anergic B cells.  
 
Anti-Sm B cells are regulated by cell death and inhibition of plasma cell (PC) differentiation. 
 The higher frequency of cell death by 2-12H and 2-12H/Vκ4 B cells after TLR 
activation could account for the poor antibody secretion by 2-12H and 2-12H/Vκ4 B cells. 
Alternatively, a block in the upregulation of the PC transcriptional program could account for 
the poor antibody secretion observed. To discriminate between these possibilities, we 
determined the phenotype of TLR-activated B cells and whether the ASC transcriptional 
program had been activated. PC differentiation results in a decrease in B220 and an increase 
in CD138 and intracellular IgM. In addition, expression of the transcription factors XBP-1 
and IRF-4 increases, while Pax-5 decreases. As shown in Fig. 5, we readily detected PC 
differentiating B cells among LPS activated non-Tg B cells by flow cytometry. These cells 
were intracellular IgMhi, B220low, XBP-1hi, IRF-4hi and CD138hi. Since all of these changes 
occurred together in mice of all three strains, we used the increase in intracellular IgM and 
XBP-1 to identify PC differentiating cells in all subsequent experiments. We were unable 
develop a flow cytometry assay for Blimp-1, the master regulator of PC differentiation, and 
were therefore unable to examine the expression of this transcription factor. However, cells 
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with increased intracellular IgM and XBP-1 likely express Blimp-1 since the both increases 
are Blimp-1 dependent 12, 13, 14, 16, 17.   
To examine the PC differentiation by anergic anti-Sm B cells in response to TLR 
activation, sorted Fo, MZ, and transitional B cells were assayed individually, since these cells 
differ in their ability to secrete antibody. Non-Tg, 2-12H, and 2-12H/Vκ4 B cells were 
cultured with either LPS or CpG and 4 days later cells harvested for flow cytometry analysis. 
These were the same cultures used to measure antibody levels in Fig. 4.  By day 4, ~50% of 
non-Tg Fo B cells were alive, but only ~40% and ~30% of 2-12H and 2-12H/Vκ4 Fo B cells, 
respectively (Fig. 6A). These populations also differed significantly in PC frequency. 
Whereas ~30% of live non-Tg Fo B cells were PCs, only ~20% and ~5% of 2-12H and 2-
12H/Vκ4 B cells, respectively, were PCs (Fig. 6A). Thus, poor antibody secretion by 2-12H 
and 2-12H/Vκ4 Fo B cells is the result of defects at two levels; a failure to efficiently rescue 
these cells from cell death and a deficiency in the activation of the PC transcriptional 
program. Consistent with this, the relative ability to rescue from cell death and to activate the 
PC transcriptional program parallels the amount of antibody secreted (Figs. 4B and 6A).    
LPS was equally able to rescue from cell death and activate the PC transcriptional 
program of non-Tg and 2-12H MZ B cells (Fig. 6B), agreeing with the similar levels of 
secreted antibody (Fig. 3C). This suggests that 2-12H MZ B cells are not anergic, as 
suggested by our previous analysis (Chapter 3)  29, 30. By contrast, LPS was less able to rescue 
and activate the PC transcriptional program of 2-12H/Vκ4 MZ B cells (Fig. 6B), paralleling 
their poor ability to secrete antibody (Fig. 3C). We conclude from these findings that 2-12H 
MZ B cells are functional, but that 2-12H/Vκ4 MZ B cells are at least partially anergic. This 
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is in agreement with our finding with these cells that 2-12H/Vκ4 BCRs, but not 2-12H 
BCRs, are uncoupled from the signalsome (Chapter 3).   
 Relative to non-Tg transitional B cells, LPS was less able to rescue 2-12H and 2-
12H/Vκ4 transitional B cells them from cell death.  This inability to rescue 2-12H/Vκ4 
transitional B cells was more pronounced than the inability to rescue anti-Sm Fo B cells.  
LPS was able to partially activate 2-12H and 2-12H/Vκ4 PC transcriptional program (Fig. 
6C). Non-Tg and 2-12H transitional B cells were not statistically different in activation of the 
PC transcriptional program, but this was likely due to the considerable variability evident 
with 2-12H transitional B cells. Thus, the intrinsic mechanisms that block activation are in 
place at the transitional B cell stage, but the ability to block the activation of the PC 
transcriptional program is not as functional as it is in Fo B cells.   
Since there are differences between TLRs in the signaling pathways they activate 7, 31, 
we compared the ability of LPS (TLR4) and CpG (TLR9) to rescue cells from cell death and 
to activate the PC transcriptional program. In contrast to LPS, CpG rescued Fo B cells from 
mice of all three strains equally well. However, 2-12H and particularly 2-12H/Vκ4 B cells 
activated the PC transcriptional program less well in response to CpG than non-Tg B cells 
(Fig. 6D). Non-Tg and 2-12H Fo B cells were not statistically different in the activation of 
the PC transcriptional program, but this likely reflects the considerable variation between 
mice. This difference parallels the difference in antibody secretion by these cells (Fig. 3B). 
Thus, whereas LPS is unable to efficiently rescue 2-12H and 2-12H/Vκ4 Fo B cells from cell 
death and to efficiently activate the PC transcriptional program, CpG exhibits a deficiency in 
only the latter. 
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DISCUSSION 
TLR-induced activation of autoreactive B cells can lead to autoantibody production 
and disease. Activation via TLRs bypasses the mechanisms that block BCR-induced 
activation of some autoreactive B cells 1, 2, 4, 5, 32, 33, 34, 35. TLR stimulation can also bypass T 
cell tolerance mechanisms leading to autoantibody production 35, 36, 37, 38, 39. Blocking TLR 
activation may be particularly important to MZ B cells, since their unique anatomical 
location may provide them with a greater exposure to LPS and CpG motifs associated with 
bacterial and viral infections 40. In addition, TLR signals in conjunction with BCR signals are 
required for autoreactive B cell activation in vivo. Thus, prevention of TLR induced 
activation is important to maintaining tolerance to self-antigens. In this study, we 
investigated the mechanisms regulating TLR activation of B cells specific for Sm, a self-
antigen commonly targeted in mouse and human SLE 41. We demonstrate that, while anergic 
anti-Sm B cells respond to LPS and CpG activation by robust proliferation, they are less able 
to rescue anergic B cells from cell death and to activate the PC transcriptional program, 
thereby preventing antibody secretion.   
The robust proliferation of 2-12H and 2-12H/Vκ4 B cells induced by LPS and CpG 
indicates that their deficiency in antibody secretion is not due to an inability to signal in 
response to TLR stimulation. In contrast to non-Tg B cells in which a large fraction (35-40%) 
do not divide at high concentrations of LPS (10 µg/ml), nearly all 2-12H/Vκ4 B cells 
undergo one or more cell divisions at this concentration. This could be due to a greater 
sensitivity to LPS, but our data showing increased cell death of non-dividing 2-12H/Vκ4 B 
cells compared to non-dividing non-Tg B cells suggests that this difference is likely to be due 
to an increased rate of cell death of non-dividing 2-12H/Vκ4 B cells. Consistent with this, 
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non-dividing 2-12H B cells, which do not differ from non-dividing B cells of non-Tg mice, 
do not differ in the frequency of cell death. Dividing 2-12H and 2-12H/Vκ4 B cells undergo 
increased cell death during clonal expansion compared to non-Tg B cells, likely accounting 
for the fewer overall number of cell divisions that these cells are able to undergo. 2-12H and 
2-12H/Vκ4 B cells respond similarly to CpG stimulation through TLR9 suggesting that a 
higher rate of cell death before and during clonal expansion are a more general response to 
TLR signaling. Thus, the anti-Sm B cells of 2-12H and 2-12H/Vκ4 B cells proliferate in 
response to TLR stimulation, but undergo a higher rate of cell death than non-Tg B cells. The 
ability to proliferate, but not secrete, in response to LPS and CpG is not a property of all 
anergic B cells. Anergic anti-HEL B cells are similar to these anti-Sm B cells, but anti-
dsDNA and anti-insulin B cells are unable to either proliferate or secrete in response to LPS 
42, 43.   
All B cells undergo cell death in vitro unless rescued by a survival signal.  Compared 
to non-Tg B cells, anergic anti-Sm B cells, particularly 2-12H/Vκ4 B cells, are more prone to 
cell death in vitro in the absence of stimuli and in response to BCR and BAFF-R stimulation 
(Chapters 2 and 3). This higher rate of cell death by anergic anti-Sm B cells in the presence 
of these stimuli could be passive, and due to a deficiency in the ability of survival stimuli to 
block an ongoing cell death program. However, BCR and TLR stimulation may actively 
promote cell death, since both upregulate the pro-apoptotic proteins Bim and Bax. LPS 
stimulation increases the level of the anti-apoptotic protein Bcl-XL, but this does not occur 
until late in the culture period after a period in which the Bcl-XL level was low and Bim and 
Bax levels were high, which likely promotes cell death. Thus, induction of cell death 
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following TLR stimulation likely plays a role in the regulation of anti-Sm B cells as we 
discuss below. 
Since anti-Sm B cells of the Fo and MZ subsets differ in their ability to signal through 
their BCR, we compared individual subsets to respond to LPS and CpG, and observed 
significant differences in both proliferation and secretion. In general, anti-Sm Fo B cells 
exhibited the greatest deficiency in antibody secretion and PC differentiation (Figs. 3 and 6).  
In addition, 2-12H/Vκ4 B cells of all subsets were more deficient in secretion and PC 
differentiation than 2-12H B cells or non-Tg B cell, likely due to their higher affinity for Sm 
(Chapter 2). Thus, 2-12H/Vκ4 Fo B cells were the most severely deficient population, 
secreting less than 10% of the antibody secreted by non-Tg B cells.  This deficiency of 2-
12H/Vκ4 B cells to secrete in response to LPS is evident at the transitional B cell stage. 
Interestingly, while 2-12H/Vκ4 MZ B cells were severely deficient in antibody secretion, 2-
12H MZ B cells were near normal indicating that the anti-Sm MZ B cells of 2-12H mice are 
functional and fundamentally different from those of 2-12H/Vκ4 mice. This parallels the 
defect in stimulation through their BCRs; 2-12H/Vκ4, but not 2-12H, MZ B cells exhibit an 
uncoupling of the BCR signalsome.  Why 2-12H and 2-12H/Vκ4 MZ B cells differ 
functionally is unclear. Although L chain use by the former is diverse (S. K. McCray and S. 
H. C., unpublished observation), they stain with Sm similarly suggesting that they have a 
similar affinity.  Thus, another quality of the BCR, such as the ability to bind endogenous 
Sm, must be responsible for determining regulation.   
Two mechanisms appear to contribute to the poor secretion by anergic anti-Sm B 
cells. First, increased cell death would likely account for some of this. In response to LPS, 
there are fewer live B cells of all three subsets in 4-day cultures of 2-12H/Vκ4 and 2-12H B 
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cells than non-Tg B cells (Fig. 6). Thus, there are fewer anti-Sm B cells than non-Tg B cells 
available for secretion. Second, anergic anti-Sm B cells of all subsets are deficient in PC 
differentiation. A smaller percentage of the live 2-12H and 2-12H/Vκ4 B cells have 
undergone PC differentiation than non-Tg B cells (Fig. 6). The defects in survival and PC 
differentiation are more severe for 2-12H/Vκ4 B cells than 2-12H B cells consistent with the 
lower levels of secreted antibody by B cells of all subsets (Fig. 3). The relative contributions 
of these two mechanisms vary between subsets. For example, 2-12H/Vκ4 Fo B cells are 
primarily regulated by a block in PC differentiation, while 2-12H/Vκ4 transitional B cells are 
regulated primarily through cell death. Since the majority of maturing transitional B cells are 
likely to become Fo B cells, and thus, the greater reliance on cell death to regulate 2-
12H/Vκ4 transitional B cells suggests that the mechanism for blocking PC differentiation is 
not fully active until after the transitional B cell stage. 2-12H/Vκ4 MZ B cells are as likely to 
survive activation by LPS, but more likely to activate the PC differentiation program (Fig. 6), 
accounting for the greater ability of these cells to secrete antibody (Fig. 3). Consistent with 
the antibody secretion data indicating that 2-12H MZ B cells are not anergic, we observed no 
difference in cell death or PC differentiation between these cells and non-Tg MZ B cells. 
Thus, Fo and MZ B cells are regulated independently; in 2-12H mice anti-Sm Fo B cells are 
regulated, while the anti-Sm MZ B cells are not, whereas both are regulated in 2-12H/Vκ4 
mice, albeit to different degrees.   
Our comparison of LPS and CpG stimulation of Fo B cells indicates that there are 
differences between TLR ligands in regulation of antibody secretion. 2-12H/Vκ4 and 2-12H 
B cells are deficient in secretion in response to CpG (Chapter 2) and this defect is evident 
among Fo and MZ B cells (Fig. 3). However, in contrast to LPS, there is not a difference in 
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cell death between Fo B cells of non-Tg, 2-12H, and 2-12H/Vκ4 mice, but 2-12H/Vκ4 Fo B 
cells exhibit a block in PC differentiation relative to the others. LPS signals via a MyD88 
dependent and a MyD88 independent, whereas CpG signals through only a MyD88 
dependent pathway 31. How the activation of one versus two of these pathways results in the 
observed differences is unclear, but it should be noted that there are differences between 
TLR9 and TLR7 stimulation and autoantibody production even though they are not know to 
be different in the activated pathways 38, 44, 45. Thus, differences in activated pathways among 
TLRs results in different regulatory mechanisms. 
The mechanism for the block in PC differentiation is not known. Our findings 
indicate that the block is prior to the upregulation of Blimp-1, the master regulator of PC 
differentiation that is necessary and sufficient for PC differentiation. Although we were 
unable to measure Blimp-1 expression, we infer from the absence of XBP-1 and IRF4 
expression, B220 downregulation, and the increase in intracellular Ig, that most LPS 
stimulated anti-Sm B cells do not express Blimp-1, since all of these changes are Blimp-1 
dependent 12, 13, 14, 46. Goodnow and colleagues have demonstrated that ERK acts as a 
molecular switch that integrates multiple signals to regulate PC differentiation. Anti-HEL B 
cells have high basal phospho-ERK levels that result in a block in PC differentiation through 
prevention of Blimp-1 upregulation 19, 20. The block in PC differentiation by anergic anti-Sm 
B cells does not appear to be regulated by this ERK molecular switch. The basal phospho-
ERK levels are not elevated in these cells relative to non-Tg B cells (Chapter 3) and LPS 
activation in the presence of U0126, a powerful inhibitor of ERK phosphorylation, shows no 
difference in antibody secretion. This difference in dependence on ERK may be a function of 
a difference in BCR affinity for antigen, the form of antigen (soluble vs. membrane bound), 
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or additional signals through other receptors. Regardless, these data indicate that anergic anti-
Sm B cells the block in PC differentiation is independent of ERK phosphorylation and 
therefore that there are at least two pathways for inhibiting PC differentiation by anergic B 
cells.  
An important consideration for how TLR activation is regulated in anergic anti-Sm B 
cells is the potential effect of antigen in the cultures. Sm is displayed on the surface of 
apoptotic cells and therefore Sm may engage the BCRs of cultured B cells. The presence of 
antigen in the culture could cause an increase in cell death, since we have shown that BCR 
stimulation of anti-Sm B cells induces increased expression of pro-apoptotic genes and cell 
death (Chapter 3). Second, signaling via the BCR could maintain high levels of Pax-5 or 
BCL-6 that inhibit Blimp-1 expression and therefore inhibit PC differentiation 12, 16, 47, 48. 
Strong BCR signaling (anti-IgM) blocks LPS-induced PC differentiation of non-Tg B cells as 
well as HEL antigen blocks induction of PC differentiation of naïve anti-HEL B cells 19. 
Thus, the inability to be able to eliminate self-antigen from these cultures could have 
important consequences to activation and antibody secretion.   
In summary, this study shows that 2-12H/Vκ4, and to a lesser extent 2-12H B cells, 
are defective in antibody secretion following TLR stimulation, even though proliferation is 
minimally affected. Activation-induced cell death and a block in PC differentiation are two 
mechanisms that act, in different degrees depending on subset identity, to regulate antibody 
secretion by anergic anti-Sm B cells. While cell death seems to be more important in 
regulating transitional B cells, a block in PC differentiation is more important to Fo B cell 
regulation. In addition, high affinity 2-12H/Vκ4 B cells display the highest degree of 
regulation, consistent with a role for BCR affinity in determining the mechanism of 
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regulation. ERK inhibition does not restore anti-Sm secretion indicating that the ERK 
mediated regulation of PC differentiation identified in anergic anti-HEL B cells is not 
responsible for the block in PC differentiation of anti-Sm B cells. Thus, these data indicate 
the existence of an alternative ERK independent pathway for blocking PC differentiation in 
anergic B cells.   
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Figure 1. Responses of 2-12H and 2-12H/Vκ4 B cells to in vitro TLR stimulation.  
A, Representative data of proliferative responses of CFSE-labeled B cells from wild-type and 
anti-Sm Tg mice incubated for 72 hr in the presence of indicated amounts of LPS and CpG. 
Cell divisions as assessed by CFSE dye dilution.  B, Cell survival as determined by flow 
cytometric analysis on isolated splenic B cells cultured in the presence of LPS and CpG for 
72 hr. Cells negative for live/dead staining, as shown in C left, were scored as viable. C, 
Percent of cells that have undergone proliferation and subsequently death. Left, gating logic 
utilized. Right, numbers show percentage of cells in gate 3.   
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Figure 2. Flow cytometric anslysis of Bim, Bax and Bcl-XL expression following LPS 
stimulation. Compiled data of protein expression of untreated (PBS) or LPS (10 µg/ml) 
treated B cells for the indicated times.  
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Figure 3. TLR induced Ab secretion by anti-Sm B cells subsets.  
A, Gating scheme used to sort the FO, MZ, and Tr B cells is indicated using 2-12H spleen 
cells. Propidium iodide (PI)+ as well as CD138+ cell were excluded. B, Ab secretion by LPS 
(10 µg/ml) or CpG (1 µg/ml) stimulated sorted Fo B cells. Cells were stimulated for 4 days 
and total IgM Ab in the supernatants were measured by ELISA. C, Ab secretion by sorted 
MZ B cells stimulated assessed as described in B. D, Ab secretion by sorted Tr B cells 
stimulated with LPS as described in B. Secretion was normalized to secretion by non-Tg 
control. Data obtained from several independent experiments (n≥6) Significant difference * 
(p<0.05), ** (p<0.01) and *** (p<0.001). 
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Figure 4. Effect of ERK inhibition on Ab secretion of 2-12H/Vk4 B cell to TLR stimulation. 
A, Purified B cells were pre-incubated or untreated for 30 min with10µM MEK Inhibitor 
U0126 and then cultured for 5 days with LPS (10 µg/ml). B, same as in A but cell were 
stimulated with CpG (1 µg/ml). C, U0126 effectively inhibits ERK activation. Purified B 
cells were pre-incubated as described in A and stimulated with anti-CD40 (10 µg/ml) for 15 
min. ERK phosphorylation was assessed by flow cytometric analysis as described in chapter 
3. (n=3) 
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Figure 5. PC differentiation assessed by Flow Cytometry analysis. 
Purified B cells were stimulated in vitro with TLR ligands for 4 days. Cells were processed 
as described in materials and methods and stained with antibodies against B220, IgM, XBP-
1, IRF-4 and CD138. Example shows non-Tg B cells stimulated with 10 µg/ml LPS (left 
column) or freshly isolated (right column). Dead cells were excluded by Live/Dead stain. B 
cells that have differentiated to PCs are boxed. 
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Figure 6. Induction of Cell Death and PC differentiation in anti-Sm B cells subsets induced 
by TLR stimulation.  
Cells were sorted and stimulated with TLR ligands as described in Fig 3. Cell death (left 
column) was determined by assessing staining with LIVE/DEAD stain kit. PC differentiation 
(right column) was determined by gating as described in Fig 5. A, Sorted Fo B cells 
stimulated with 10 µg/ml LPS. B, Sorted MZ B cells stimulated with 10 µg/ml LPS. C, 
Sorted Tr B cells stimulated with 10 µg/ml LPS. D, Sorted Fo B cells stimulated with 1 
µg/ml CpG. Each symbol represents cells from individual sorts. Significant difference * 
(p<0.05), ** (p<0.01) and *** (p<0.001). 
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CHAPTER 5 
 
Summary and future directions 
 
 
The immune system has developed mechanisms to silence B cells specific for self 
antigens through mechanisms of tolerance. Tolerance encompasses many processes and 
mechanisms that regulate and suppress the activation of self-reactive cells 1, 2, 3, 4, 5, 6, 7. When 
these mechanisms fail autoimmune disease ensues. Immunoglobulin Tg mice have been very 
effective tool in the elucidation of the mechanisms of B cell tolerance. These mechanisms 
include central and peripheral deletion, receptor editing, developmental arrest, anergy and 
follicular exclusion 7, 8, 9. Anergy is of great interest because it offers a window for a break in 
tolerance due to the retention of self-reactive cells in the periphery 6, 7, 10. Early analyses of B 
cell anergy using Ig-Tg mouse models has generally considered B cells as a single 
homogeneous population whish shared common characteristics amongst the different models. 
These characteristics included low BCR levels, a short life span, follicular exclusion and 
defective or uncoupled BCR signaling cascade 5, 11, 12, 13. Nonetheless, other recent models do 
not share these same characteristics 12, 14, 15, 16, 17. The differences observed between these 
models indicated that anergy encompasses a broad spectrum of complex and multi-factorial 
states of cell unresponsiveness.  Thus, better understanding of B cell anergy is fundamental 
for the design of new therapies for autoantibody-mediated diseases. 
Sm, a component of a ribonucleoprotein, is a target of the immune system in the 
autoimmune disease systemic lupus erythematosus (SLE) 18, 19, 20. For the work presented 
here I utilized Ig-Tg mouse models specific for Sm. I utilized mice transgenic for the 2-12H 
gene (2-12H) and the 2-12H gene and a Vκ4 gene (2-12H/Vκ4). 2-12H Tg mice present a 
polyclonal B cell population of anti-Sm B cells with varying degrees of BCR affinity 14, 21. In 
contrast to the 2-12H/Vκ4 B cells are basically monoclonal. Using mice expressing one BCR 
clonotype is useful to tease apart the multiple mechanisms involved in regulation of 
autoreactive B cells, which in real life will involve numerous clonotypes of different 
affinities for antigen. Furthermore, the 2-12H/Vκ4 mice offer the first ever opportunity to 
assess regulation of self-reactive MZ B cell. The goal of this work was to gain insight into 
the regulation of anti-Sm B cells and to advance the current understanding of B cell anergy. 
The studies presented in chapter 2 revealed that anti-Sm B cells are regulated by 
anergy but that the BCR affinity for Sm is a determining factor. It has previously been shown 
that low affinity 2-12H/Vκ8 anti-Sm B cells are limited to differentiation to the Fo B cell 
stage and, although anergic, they are able to survive in the presences of competitor B cells 14. 
In contrast, high affinity 2-12H/Vκ4 B cells differentiate to Fo, MZ and B-1 B cells. 
Nonetheless, they are unable to survive in a competitive environment. Suggesting that high 
BCR affinity induces a mechanism of regulation not observed in low affinity anergic B cells. 
This defect correlates with a minimal responsiveness to BAFF, which is unable to rescue 
these cells from cell death.  Because BAFF is required for B cell maturation and maintenance 
22, 23, 24, 25 we hypothesize that the observe defect must be induced after maturation of anti-Sm 
B cells. However, it is not clear why 2-12H/Vκ4 B cells have a normal life span in a 
monoclonal environment.  A likely explanation is that there is some BAFF signaling and that 
this low level is sufficient to allow B cell survival when B cell numbers are low. 
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The minimal BAFF responsiveness by 2-12H/Vκ4 B cells does not seem to be due to 
BAFF receptor expression defects or anomalies. The most likely explanation is that the 
signaling ability of these receptors is compromised. Because these cells are still able to 
mature, I predict that the defect in BAFF responsiveness is with only the survival pathway, 
such as the Akt and Pim2 pathways leading to upregulation of the anti-apoptotic protein Mcl-
1  22, 26 and the alternative NF-κB activation pathway which is involved in Bcl-XL 
upregulation 27, 28, 29. Although, recent studies undermine the role of Bcl-XL in BAFF 
mediated survival 30, 31, 32, 33.  It will be interesting in the future to determine to define 
precisely the defect in BAFF signaling that prevents survival in a competitive environment. 
Preliminary data indicates a defect in the Akt survival pathway (R. Bussick, personal 
communication).  
In chapter 3, I assessed the ability of the BCR on cells of each subset to signal in 
response to BCR ligation to determine whether anergic anti-Sm Fo and MZ B cells are 
regulated similarly.  Although anti-Sm Fo B cells from both 2-12H and 2-12H/Vκ4 mice are 
signaling competent, they are induced to undergo rapid cell death, which can be explained by 
an imbalance in pro- and anti-apoptotic proteins that favors apoptosis. 2-12H MZ B cells are 
able to induce signaling following BCR ligation and are not anergic, as previously 
demonstrated 34, 35. In contrast, 2-12H/Vκ4 MZ B cells exhibit a weak protein tyrosine 
phosphorylation response and little increase in Syk and ERK phosphorylation. Furthermore, 
they are unable to respond to endogenous self antigens, since in contrast to 2-12H MZ B 
cells; they do not constitutively generate anti-Sm pre-plasma cells and are not activated by an 
increase in apoptotic cell load. These data demonstrate that 2-12H/Vκ4 MZ B cells are 
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regulated by uncoupling of the BCR from the signalosome and are anergic. Anergy of self-
reactive MZ B cells has not been previously described.  
The uncoupling of the BCR from signalosome in 2-12H/Vκ4 could be due to negative 
regulators of BCR signaling. CD5, a negative regulator of signaling expressed mainly by B-
1a cells, is a potential target of future research 36, 37, 38, 39. 2-12H/Vκ4 MZ B cells express high 
levels of CD5 (data not shown) and could be responsible for the uncoupling observed. 
Alternatively, the Igα/Igβ signaling components of the BCR may be dissociated from the Ig 
component due to chronic engagement with self-antigen 40, 41.   
In Chapter 4, I assess the mechanisms regulating TLR induced activation and 
differentiation to PCs of anergic anti-Sm B cells. Anergic 2-12H and 2-12H/Vκ4 anti-Sm B 
cells proliferate in response to TLR stimulation.  However, both 2-12H/Vκ4, and to a lesser 
degree, 2-12H B cells, are defective in antibody secretion. Two mechanisms regulate 
antibody secretion: activation-induced cell death and a block in PC differentiation, although 
the contributions of these mechanisms differ depending on B cell subset identity and is 
influenced by BCR affinity. The block in PC differentiation is not fully established until B 
cells reach the Fo B cell stage suggesting that this mechanism is established after maturation. 
Cell death of anti-Sm B cells might be a consequence of increased Bim expression following 
TLR stimulation or a lag in the upregulation of Bcl-XL. Because anti-Sm B cells can 
proliferate to TLRs, it suggests that a particular signaling pathway involved in survival is 
defective. NF-κB and Akt pathways are to potential candidates due to their role in Bcl-XL 
and A1 expression, two key anti-apoptotic proteins and therefore in future experiments we 
will want to determine whether signaling through these pathways is altered in anergic anti-
Sm B cells 29, 42, 43.  
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The block in PC differentiation seems to occur prior to the upregulation of a plasma 
cell-specific transcription program. Although we were unable to measure Blimp-1 
expression, we infer from the absence of XBP-1 and IRF4 expression, B220 downregulation, 
and the increase in intracellular Ig, that most LPS stimulated anti-Sm B cells do not express 
Blimp-1, since all of these changes are Blimp-1 dependent 44, 45, 46, 47, 48. Nonetheless, future 
studies will try to address the expression of Blimp-1 as well as BCL-6 in TLR stimulated 
anti-Sm B cells.  
Sm is displayed on the surface of apoptotic cells 35 and therefore Sm may engage the 
BCRs of cultured B cells. The presence of antigen in the culture could cause an increase in 
cell death, since we have shown that BCR stimulation of anti-Sm B cells induces increased 
expression of pro-apoptotic genes and cell death (Chapter 3). Second, signaling via the BCR 
could maintain high levels of Pax-5 or BCL-6 that inhibit Blimp-1 expression and therefore 
inhibit PC differentiation. Blocking Sm in culture might result potentially problematic. An 
alternative possibility is to inhibit pharmacologically BCR signaling in order to test this 
possibility.  
Anergic anti-HEL B cells blocked from PC differentiation by a mechanism dependent 
on ERK activation 49, 50. In this chapter, I have demonstrated that anti-Sm PC block is 
independent of ERK activation, suggesting the existence of an ERK-independent pathway in 
the regulation of PC differentiation of anergic B cells.  The identification of this pathway is 
of great interest and would be a priority in future experiments as well as to determine if these 
mechanisms are maintained in vivo.   
Overall, this work has demonstrated multiple mechanisms for the regulation of anti-
Sm B cell activation by BCR and TLR signals.  These mechanisms are unique compared to 
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anergic B cells specific to other self-antigens, which could be due to the form and 
distribution of the antigen 6, 7, 10.  Furthermore, I have shown how the BCR affinity can 
influence the degree to which a mechanism acts on anergic anti-Sm B cells.  Since both BCR 
and TLR signaling can activate B cells, multiple mechanisms are required to prevent antigen 
specific activation through the BCR and antigen non-specific, bystander activation through a 
TLR 51.  The regulation of TLR signaling is of added importance due to the recent studies 
showing that sequential signaling through the BCR and a TLR. can activate autoreactive B 
cells 52, 53, 54, 55.  For Sm and other ribonucleoprotein antigens, the involvement of TLR7, 
which binds ssRNA is paramount 55, 56, 57, 58.  Thus, an understanding of the biochemical 
pathways involved in blocking anti-Sm B cell activation by BCR and TLR signals will be 
important to the identification of new therapeutic targets to prevent the production of 
pathogenic autoantibodies characteristic of human SLE.  The present work has laid the 
groundwork for the identification of relevant signaling pathways.   
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